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Abbreviations 
AEC  Arteriolar endothelial cell 
AGM  Aorta gonad mesonephros 
Ang1  Angiopoietin 1 
BFU-E  Erythroid Burst Forming Unit 
Bglap-Cre Bone gamma carboxyglutamate protein 
BM  Bone marrow 
BMP  Bone morphogenetic protein 
CAR  CXCL12 abundant reticular cells 
Col2.3-Cre Collagen 2.3 
CD  Cluster of differentiation 
CFU-G Colony forming unit – granulocyte 
CFU-GM Colony forming unit – granulocyte macrophage 
CFU-GEMM Colony forming unit – granulocyte erythrocyte macrophage megakaryocyte 
CFU-M Colony forming unit – macrophage 
cKit   c-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
CLC  Cardiotrophin like cytokine 
CLR  C-type lectin receptors 
CNTF  ciliary neurotrophic factor 
Csf2  Conlony stimulating factor 2 
Csf3  Conlony stimulating factor 3 
CT1  Cardiotrophin-1 
Cxcl4  C-X-C motif chemokine 4 
Cxcl12  C-X-C motif chemokine 12 (SDF1) 
Cxcr4  C-X-C chemokine receptor type 4 
DC  Dendritic cell 
DNA  Desoxyribonucleic acid 
EC  Endothelial cells 
ET  Endotoxin tolerance 
FACS  Fluorescence-activated cell sorting 
Flt3(L)  FMS-like tyrosine kinase (ligand) 
G-CSF  Granulocyte colony stimulating factor 
GFAP  Glial fibrillary acidic protein 
GFP  Green fluorescent protein 
GMP  Granulocyte monocyte progenitor cells 
gp130  Glycoprotein 130 
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Gr1  Ly6G lymphocyte antigen 6 complex 
HSC  Hematopoietic stem cells 
HPC  Hematopoietic progenitor cells 
HSPC  Hematopoietic Stem and Progenitor Cells 
IGF-1  Insuline-like growth factor 1 
IGFBP-3 Insuline-like growth factor binding protein 3 
Infα  Interferon α 
Infβ  Interferon β 
Infγ  Interferon γ 
IL  Interleukin 
Lepr  Leptin receptor 
LIF  Leukemia inhibitory factor 
Lineage collective term indicating terminally differentiated cells, in this study lineage cells are 
all hematopoietic cells expressing CD3+,CD4+,CD8+,CD11b+,Gr-1+, NK1.1+,Ter119+, 
B220+ and IL-7Rα+ (Unless indicated) 
LSK  Lineage-cKit+Sca1+ 
LPS  Lypopolysaccharide 
LT-HSC Long-term hematopoietic stem cell 
MEP  Megakaryocyte erythrocyte progenitor cells 
mIL6R  membrane-bound IL6 receptor 
MPP  Multipotent progenitors 
MSC  Mesenchymal stem/stroma cells 
MyD88 myeloid differentiation primary response gene 88 
NLR  NOD-like receptors 
OCL  Osteoclast 
OSM  Oncostatin M 
PAMP  Pathogen-associated molecular patterns 
PαS  PDGFRα+ Sca1+ 
PB  Peripheral blood 
PBS  Phosphate buffered saline 
PDGFRα Platelet-derived growth factor receptor alpha 
PDGFRβ Platelet-derived growth factor receptor beta 
poly I:C  polyinosinic-polycytidylic acid 
PRR  Pattern-recognition receptors 
qRT-PCR Quantitative real-time polymerase chain reaction 
RLR  RIG-I-like receptors 
RNA  Ribonucleic acid 
SAA  Serum amyloid A 
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Sca-1  Ly6a lymphocyte antigen 6 complex 
Scf  Stem cell factor 
SEC  Sinusoidal endothelial cell 
sIL6R  soluble IL6 receptor 
SLAM  Signaling lymphocyte activation molecule 
SLAM HSC LKS CD48- CD150+ 
SNS  Sympathetic nervous system 
TGFβ  Tissue growth factor beta 
TLR  Toll-like receptor 
TNF α  Tumor necrosis factor alpha 
TPO   Thrombopoietin 
Wt  Wild type 
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Summary 
Hematopoiesis is the process of continuous generation of mature blood cells which all originate 
from hematopoietic stem and progenitor cells (HSPC). This process is taking place in the bone 
marrow (BM) where HSPCs are surrounded by different types of hematopoietic and non-
hematopoietic cells which together form a complex supportive microenvironment. The enormous, 
balanced turnover of erythrocytes, platelets and leukocytes has to be tightly controlled as 
dysregulation can lead to pathological conditions such as aplasia or leukemia. Besides known 
intrinsic regulatory pathways, a growing body of evidence suggests that important extrinsic 
regulatory mechanisms have evolved to maintain hematopoietic homeostasis. 
 
We wanted to investigate how the BM microenvironment supports the hematopoietic system during 
a stress situation, like in adaptation to severe systemic inflammation. Therefore, the principal goal 
was to get a deeper insight into the complex interactions between the hematopoietic system and 
its supportive microenvironment during demand-adapted hematopoiesis. Hence we wanted to find 
potental regulators of inflammation-driven hematopoiesis which are produced by the BM 
microenvironment. For this study, we injected wild type (WT) mice with lipopolysaccharide (LPS) or 
polyinosinic-polycytidylic acid (poly(I:C)) to mimic gram-negative bacterial or viral infection, 
respectively. We prospectively isolated different non-hematopoietic cell types from the BM 
according to their characteristic immunophenotypes (endothelial cells (ECs), mesenchymal stromal 
cells (MSCs), Cxcl12-abundant reticular cells (CARs) and a not further defined population called 
Unkn). We analyzed differential gene expressions among these different cell types and found that 
Il6 expression was significantly and specificlly upregulated in CAR cells during LPS treatment. 
Therefore, we chose this gene for further analysis of its regulatory role during inflammation-driven 
hematopoiesis (see next paragraph). In addition, we wanted to generate whole genome expression 
profiles of non-hematopoietic cells of the BM microenvironment during steady-state, bacterial or 
viral infection, as well as during early development and ageing. To approach this aim in the best 
possible way, we optimized the isolation and preparation of the different non-hematopoietic BM cell 
types as well as advance the characterization of their immunophenotypes. Using the endothelial 
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cell marker endoglin (CD105) we are now able to distinguish arteriolar endothelial cells (AECs) and 
sinusoidal endothelial cells (SECs) within the endothelial cell population and therefore can sort one 
population in additon. We performed a first RNA sequencing run on one cohort of PBS, LPS and 
poly(I:C) treated mice and performed quality controls. As the prospective isolation protocol is now 
enhanced, and the controls of the first batch of sequenced data confirmed known gene expression, 
we are now confident in proceeding with prospectively isolating the different non-hematopoietic BM 
cell types from diverse conditions. Therefore, we will sort AECs, SECs, MSCs, CAR cells and 
Unkn fom young (15-18 days) and old (more than 2 years) WT mice as well as from PBS, LPS or 
poly(I:C) treated adult WT animals. Subsequently all samples willl be sequenced and we will be 
able to determine gene expression profiles followed by functional analysis of differential gene 
expression changes among them in future experiments. 
 
We confirmed the high and significant upregulation of IL-6, specifically in CAR cells, after LPS 
stimulation by measuring IL-6 protein levels in plasma and BM lysates of reciprocal BM chimeric Il6 
-/- mice (Il6 -/- à WT, WT à Il6 -/-) as well as in conditional Il6-/- mice (Lepr-Cre;Il6 fl/fl ), in which IL-6 
is specifically knocked out in CAR cells. Studying the hematopoietic response in LPS-treated Il6-/- 
and Lepr-Cre;Il6 fl/fl mice, we observed a significant decrease in absolute cell numbers of cells of 
the myeloid lineage from the earliest HSPCs to mature myeloid cells upon chronic-repetitive LPS 
stimulation (9 injections over 3 weeks). Moreover, the total number of colony-forming units 
granulocyte (CFU-G) was significantly reduced in the BM of LPS-treated Il6-/- and Lepr-Cre;Il6 fl/fl 
mice compared to their respective controls. Our data reveal that CAR cells play an essential role 
for a sustained hematopoietic response during chronic repetitive LPS treatment in producing high 
levels of IL-6.  
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Zusammenfassung 
Hämatopoese ist der Prozess der kontinuierlichen Herstellung von gereiften Blutzellen, welche alle 
von hämatopoetischen Stamm- und Vorläuferzellen (HSPC) abstammen. Dieser Prozess findet im 
Knochenmark (BM) statt, wo HSPCs von verschiedenen hämatopoetischen und nicht-
hämatopoetischen Zellen umgeben sind, welche zusammen eine komplexe, unterstützende 
Mikroumgebung bilden. Der enorme, ausgeglichene Umsatz von Erythrozyten, Blutplättchen und 
Leukozyten muss streng kontrolliert werden, da Störungen in der Regulation zu pathologischen 
Zuständen führen können wie Aplasie oder Leukämie. Abgesehen von bekannten intrinsischen 
regulatorischen Signalwegen, finden sich stetig neue Ergebnisse, die auf wichtige extrinsische 
regulatorische Mechanismen hindeuten, welche sich entwickelt haben, um das hämatopoetische 
Gleichgewicht aufecht zu erhalten. 
 
Wir wollten untersuchen wie die Knochenmarkmikroumgebung das hämatopoetische System 
während einer Stresssituation, wie der Anpassung an eine schwere systemische Entzündung, 
unterstützt. Deshalb war unser Hauptziel ein besseres Verständnis der komplexen Interaktionen 
zwischen dem hämatopoetischen System und seiner unterstützenden Mikroumgebung während 
einer der Nachfrage angepassten Hämatopoese. Darum wollten wir potenzielle Regulatoren einer 
entzündungsgetriebenen Hämatopoese entdecken, welche von nicht-hämatopoetischen Zellen des 
Knochenmarks produziert werden. Für diese Studie wurden Wildtyp (WT) Mäuse mit 
Lipopolisaccharide (LPS) oder Polyinosinic-Polycytidylic acid (poly(I:C)) injiziert, um entweder eine 
gram-negative bakterielle oder eine virale Infektion zu simulieren. Wir isolierten verschiedene 
nicht-hämatopoetische Zelltypen aus dem Knochenmark anhand ihres charakteristischen 
Immunophänotypes (Endothelzellen (EC), mesenchymale stromale Zellen (MSC), retikuläre Zellen 
angereichert an Cxcl12 (CAR) und eine nicht weiter definierte Zellpopulation die wir darum 
Unknown (Unkn) nannten). Wir analyisierten dann differenzielle Genexpressionen von diesen 
verschiedenen Zelltypen und fanden heraus, dass IL-6 signifikant and spezifisch in CAR Zellen 
während der LPS Behandlung hoch reguliert wird. Deshalb wählten wir dieses Gen/Protein aus, 
um seine regulatorische Rolle während einer entzündungsgetriebenen Hämatopoese zu 
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untersuchen (siehe nächsten Paragraphen). Zusätzllich wollen wir auch Genomexpressionsprofile 
von nicht-hämatopoetischen Zellen aus dem Knochenmark generieren, während sich die 
Hämatopoese entweder im Gleichgewicht befindet, währed einer bakteriellen oder viralen 
Infektion, während der frühen Entwicklung oder im hohen Alter. Um dieses Ziel in der best 
möglichen Art und Weise in Angriff zu nehmen, mussten wir die Isolation und Präparation der 
verschiedenen nicht-hämatopoetischen Zelltypen aus dem Knochenmark optimieren und 
gleichzeitig auch die Charakterisierung ihrer Immunophänotypen verbessern. Wir haben nun die 
Möglichkeit arterielle Endothelzellen (AEC) und sinusidale Endothelzellen (SEC) innerhalb der 
Endothelzellpopulation zu unterscheiden, da wir den Endothelzellmarker CD105 benutzen und 
können damit noch eine zusätzliche Zellpopulation unterscheiden. Wir haben eine erste RNA 
Sequenzierung mit einer Kohorte von PBS, LPS und poly(I:C) behandelten Mäusen und 
entsprechenden Qualitätskontrollen durchgeführt. Da unser Isolationsprotokoll verbessert wurde 
und alle Kontrollen der ersten RNA Sequenzierung unseren Erwartungen entsprachen, können wir 
nun fortfahren mit dem Isolieren der verschiedenen nich-hämatopoetischen Zelltypen aus dem 
Knochenmark während verschiedenen Situationen. Wir werden AECs, SECs, MSCs, CARs und 
Unkn Zellen von jungen (15-18 Tage) und alten (mehr als 2 Jahre) WT Mäusen als auch von PBS, 
LPS oder poly(I:C) gehandelten adulten WT Mäusen isolieren. Anschliessend werden alle Proben 
sequenziert werden und wir werden bald die Möglichkeit haben Genexpressionsprofile zu 
ermitteln, welche wir dann auf differenzielle Genespressionen zwischen den verschiedenen 
Situationsbedingungen analysieren werden. 
 
Es war uns möglich die signifikante Hochregulation von IL-6 in CAR Zellen nach LPS Stimulation 
zu bestätigen. Dafür massen wir die IL-6 Proteinspiegel im Blutplasma und in Knochenmarklysaten 
von reziproken Knochenmark Chimären von Il6-/- Mäusen (Il6-/- à WT, WT à Il6-/-) als auch von 
gewebespezifischen Il6-/- Mäusen (Lepr-Cre;Il6fl/fl) welche kein IL-6 in CAR Zellen generieren. Wir 
studierten die hämatopoetische Antwort auf eine LPS Stimulation in Il6-/- und Lepr-Cre;Il6fl/fl 
Mäusen und konnten einen signifikanten Rückgang der absoluten Zellzahlen von HSPCs über 
Vorläuferzellen bis hin zu reifen myeloischen Blutzellen nach chronischer, repetitiver Stimulation 
mit LPS (9 Injektionen über 3 Wochen) beobachten. Zudem waren die Gesamtzahlen von 
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koloniebildenden Einheiten von Granulozyten (CFU-G) im Knochenmark von LPS behandelten Il6-/- 
und Lepr-Cre;Il6fl/fl Mäusen im Vergleich zu ihren jeweiligen Kontrollen signifikant reduziert. Unsere 
Daten zeigen, dass CAR Zellen eine essentielle Rolle spielen im Aufrechterhalten einer 
hämatopoetischen Antwort während einer chronisch, repetitiven LPS stimulation, in dem sie hohe 
Mengen an IL-6 generieren. 
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Introduction 
The general architecture and ontogeny of the hematopoietic system 
The blood-forming or hematopoietic system that gives rises to all types of mature blood cells is 
maintained by a rare population of hematopoietic stem cells (HSCs) that reside at the top of this 
hierarchically constructed organ system. HSCs need to be preserved over a lifetime and this 
fundamental requirement is accomplished through their ability to self-renew. As the vast majority of 
mature blood cells, with the exception of some T cells and locally self-renewing macropages, are 
terminally-differentiated and post-mitotic with short half-lives they need to be constantly 
regenerated from HSCs to maintain homeostasis of the blood system. Therefore, besides self-
renewing cell divsions, HSCs have the potential to divide and generate multipotent hematopoietic 
progenitors (HPCs) with limited self-renewal capacity but high proliferative potential, which in turn, 
will give rise to inceasingly lineage-committed progenitors finally generating all the various kinds of 
mature blood cells of the myeloid and lymphoid lineage (Figure 1). This enormous cellular 
amplification produces approximately 1x109 erythrocytes and 1x 108 white blood cells per hour in 
steady state in humans [1] (Nombela-Arrieta & Manz, 2017, accepted). As discussed below in 
more detail, the hematopoietic system is very flexible allowing it to react to hematopoietic 
challenges such as blood loss and infection with massively enhanced blood cell production 
(demand-adapted hematopoiesis) [2-5]. Hematopoiesis has to be tightly controlled by intrinsic 
regulatory pathways determined and operating within HSPCs (i.e. transcriptional programs 
executed by lineage-sprecific transcription factors) as well as extrinsic mechanisms, i.e. regulatory 
signals such as growth factors and cytokines released from other cell types within and outside of 
the BM that govern HSPC differentiation. The classical example of such extrinsic regulation 
originating outside of the BM cavity is erythropoetin produced by kidney cells. Erythropoetin is the 
primary stimulus for red blood cell production and hence its plasma levels are tighly controlled and 
inversely related to oxygen levles. Kidney cells can sense low oxygen pressure and as 
consequence start to increase erythropoietin production, which resutls in the stimulation of red 
blood cell production in the BM [6]. Incapability to maintain proper hematopoietic regulation can 
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lead to pathological conditions such as bone marrow failure or development of hematopoietic 
malignancies (myelodysplastic syndroms / leukemia) [7-13]. 
 
Vertebrate ontogeny of the hematopoietic system has been studied best in mice. During mouse 
embryonic development hematopoiesis first originates in the yolk sac on embryonic day E7.5. This 
first wave of hematopoiesis is called “primitive” because it mainly produces red blood cells to 
support the increasing oxygen demand of the growing mouse embryo [14]. The next wave called 
“definitive hematopoiesis” produces fully functional HSCs with long-term, multilineage 
differentiateion capacities in the area surrounding the dorsal aorta termed the aorta-gonad 
mesonephros (AGM) region on E10.5 [3, 15, 16]. Thereafter, HSCs migrate from the AGM to the 
placenta and fetal liver by E11-E12 and from there hematopoiesis shifts to the spleen and thymus 
by E14 where it is still present several weeks postnatally [17]. By E18 HSCs start to repopulate the 
BM where they reside and maintain hematopoiesis throughout adult life [3, 14]. 
Figure 1: The hematopoietic hierarchy 
The hematopoietic system is hierarchically organized and is maintained by HSCs which possess the abilty of self-
renewal and multipotency. They then differentiate into multipotent progenitors with limited self-renewal capacity, which 
give rise to lineage committed progenitors which finally generate mature blood cells of all lineages. 
Long-term HSC (LT-HSC), short-term HSC (ST-HSC), multipotent progenitor (MPP), common myeloid progenitor 
(CMP), lymphoid-primed multipotent progenitor (LMPP), common lymphoid progenitor (CLP), megakaryocyte–
erythrocyte progenitor (MEP), granulocyte– macrophage progenitor (GMP), common dendritic progenitor (CDP), 
dendritic cell (DC), natural killer cells (NK cells) 
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Technological advances, most importantly in flow-cytometry and immunefluorescence microscopy, 
have largely determined our increasing understanding of HSPC biology. Based on differential 
expression of cell surface markers it is possible to prospectively identify and isolate HSCs as well 
as multipotent progenitors and mature blood cells. HSC populations are routinely phenotypically 
defined by the absence of expression of markers of mature hematopoietic lineages (Lin-) and the 
presence of Sca-1 c-Kit (LSK) in conjunction with the presence or absence of signaling lymphocytic 
activation molecule (SLAM) markers CD150 and CD48, respectively. The phenotype Lin-Sca1+ and 
cKit+CD150+CD48- is widely used to prospectively define and isolate LT-HSCs and is often referred 
to as LSK SLAM. Immunophenotypically-defined LT-HSCs (LSK SLAM) have a frequency of 
approximately 0.008% with regard to total BM cells correspondig to about 11’000 – 22’000 LT-
HSCs per mouse [18-20]. It needs to be noted that, despite the possibilty to prospectively identify 
and isolate populations highly-enriched for HSCs by their phenotype, functional properties are 
required to define HSCs. The gold standard to prove HSC activity is the ability of long-term 
reconstitution and multi-lineage differentiation following transplantion into lethally irradiated mice. 
In this regard, a single transplanted HSC is capable of meeting this functional requirement [21-23]. 
 
A large body of evidence demonstrates that maintaining HSC quiescence is fundamental for HSC 
function, and indeed, snap shot analyses have shown that most adult HSCs are in the G0 phase of 
the cell cycle at any given time [24-26]. Hence, on average only 5-20% of HSCs are cycling at any 
given time and participate in blood cell production [24]. More detailed analyses, have shown that 
HSCs can be divided into two different functional groups of fast (5 or more divisions in 7 weeks) or 
slow dividing HSCs (no division within 12-14 weeks) [27, 28]. Since HSCs are mainly quiescent, 
multipotent and lineage-committed HPCs are largely responsible for the production of mature 
hematopoietic cells during unperturbed steady-state conditions [29, 30]. However, evolutionary 
pressure has shaped the hematopoietic system to possess remarkable adaptability to various 
stress situations such as bleeding and infection by enhanced proliferation and differention of both 
HSCs and HPCs with the overall goal to increase hematopoietic output according to increased 
demand [2, 4, 5].  
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Infection- and inflammation-driven Hematopoiesis 
As mentioned above, severe systemic bacterial infection acts as a trigger to launch a 
hematopoietic response program – termed ‘emergency hematopoiesis’ – intended to augment 
numbers of innate immune cells, mostly granulocytes, to account for the increased demand for 
these cells during infection. Recognizing the dissemination of bacteria and switching steady-state 
to emergency hematopoiesis is a fundamental process. Any cell type that is able to sense life-
threatening bacterial infection is required to be endowed with the molecular machinery to fulfill this 
function. This involves pathogen-sensing itself, i.e. the capability of detecting invading pathogens, 
but also translating this signal into enhanced hematopoiesis. 
 
Pathogen-sensing is accomplished via pattern recognition receptors (PRRs) recognizing highly 
conserved pathogen-associated molecular patterns (PAMPs) which are often essential structural 
components of microorganisms such as lipoproteins and lipopolysaccharides (LPS). Several 
classes of PRRs exist including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-
like receptors (NLRs), and RIG-I-like receptors (RLRs) [31]. TLRs are the best-characterized family 
of PRRs [31, 32]. In light of the many cell types that have been reported to express TLRs, multiple, 
sometimes contradictory mechanisms of pathogen sensing followed by initiation of emergency 
hematopoiesis have been described. In this regard, both mouse [33, 34] and human [35-37] 
HSPCs express TLRs and it has been demonstrated that TLR stimulation promotes proliferation 
and myeloid differentiation in vitro and in vivo [34, 38]. While some data suggests that TLR 
stimulation on HSPCs induces proliferation and myeloid differentiation in a cytokine-independent 
manner [33], a recent study has revealed that HSPCs respond to in vitro TLR agonist treatment 
with secretion of inflammatory cytokines acting in an autocrine / paracrine manner [39]. However, 
the degree to which direct pathogen sensing by HSPCs is functionally relevant in comparison to 
other mechanisms remains to be determined (Figure 2) (discussed below).  
 
According to the classic model of pathogen sensing and translation into emergency hematopoiesis, 
monocytes and macrophages, by virtue of their migratory behaviour or ubiquitious tissue 
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distribrution as well as expression of PRRs and subsequent production of inflammatory cytokines, 
are believed to serve as the primary pathogen-sensing cell types [40-45]. However, rigorous in vivo 
experimentation supporting this assumption is lacking. Indeed several lines of evidence 
demonstrated that mononuclear phagocytes are dispensable for initiating emergency 
granulopoiesis, at least during short-term LPS-induced inflammation [46]. In recent years, non-
hematopoietic cells have gained broader attention as a putative candidate pathogen-sensing cell 
type based on data, demonstrating robust expression of TLRs on a variety of non-hematopoietic 
cell types such as endothelial cells (ECs) [47, 48] bladder epithelial cells [49], airway cells [50], and 
mesenchymal stromal cells (MSCs) [51-55]. It has been shown that the above-mentioned non-
hematopoietic cells types participate in launching inflammatory responses following TLR 
stimulation [47-50, 55]. Along these lines, Boettcher et al. have recently undertaken a more 
systematic approach to dissect the relative contribution of hematopoietic vs. non-hematopoietic 
cells during pathogen-sensing and initiation of emergency hematopoiesis. Based on their initial 
study in which reciprocal Tlr4-/- BM chimeric mice were used to restrict TLR4 expression to either 
hematopoietic or non- hematopoietic cells, the authors unequivocally demonstrated that TLR4-
expressing hematopoietic cells including monocytes and macrophages are dispensable for 
pathogen sensing during LPS-induced emergency granulopoiesis [46]. Unlike the popular 
assumption, Tlr4-expressing non-hematopoietic cells were critical for LPS recognition leading to 
granulocyte colony-stimulating factor (G-CSF) production and stimulation of emergency 
granulopoiesis. In a follow-up study, Boettcher et al. set out to identify the precise identity of this 
non-hematopoietic cell type by applying the Cre-loxP methodology to generate mice with a myeloid 
differentiation primary response gene 88 (Myd88)-deficiency in various candidate non-
hematopoietic cell types, which by virtue of its function as adaptor molecule in TLR signaling 
abrogates LPS-mediated G-CSF secretion [56]. The authors were able to demonstrate that LPS-
induced emergency granulopoiesis is primarily governed by G-CSF secreted from Tlr4-expressing 
ECs. Of note, Csf3 (the gene name for G-CSF) induction following LPS stimulation was highest in 
BM ECs as compared to ECs isolated from other parts of the vasculature suggesting that BM ECs 
are functionally specialized essential regulators of emergency hematopoiesis. In conjunction with 
accumulating evidence from other studies [55, 57] these data point to a critical role of the 
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supportive BM microenvironment during the regulation of infection- and inflammation-induced 
hematopoiesis. 
 
The Bone Marrow Microenvironment – Concepts 
The concept of a BM niche, i.e. a unique physical place within the microarchitecture of the BM 
cavity, where HSCs reside and develop into more mature hematipoietic cell types, was first 
proposed by Schofield four decades ago [58]. Schofield’s proposal listed some basic concepts of a 
putative HSC niche: (1) a defined anatomic site, (2) a location where stem cells could be sustained 
and reproduce, (3) a place where differentiation was inhibited, (4) a limited space that also limited 
the numbers of stem cells. 
Figure 2: Direct and indirect activation of emergency hematopoiesis 
Pathogens are sensed through pattern recognition receptors (PRRs) like Toll-like receptors (TLRs). These receptors 
are expressed directly on HSPCs, on other hematopoietic cells or on non-hematopoietic cells of the BM 
microenvironment. The binding of pathogen-associated molecular patterns (PAMPs) leads to a molecular transition. 
Subsequently, cytokines are released by the sensing cell or other cells and emergency hematopoiesis is activated. 
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Since then, the BM niche, also referred to as the BM microenvironment, has been studied 
extensively for its role in regulating hematopoiesis. The BM is located within the cavities of long 
and axial bones. The trabecular regions of the metaphysis where shown to mainly home 
transplanted HSCs rather than the epiphysis or diaphysis [59]. The outer region of the bone cavity 
forms the endosteal region which is mainly built by osteoblasts [60, 61]. Several studies have 
demonstrated, that HSCs with greater self-renewal capacity preferred to localize close to the bone 
surface rather than in central marrow regions [62, 63]. By contrast, other studies suggested a more 
random distribution of HSCs within the BM relative to the endosteum but consistenly demonstrated 
HSCs being close to vascular sinusoids [18, 64, 65]. These observations led to the proposal of 
differential niche models: the “endosteal niche” in which HSCs are residing in close proximity to the 
endosteum and in contact with osteoblasts [60, 61, 66] and the “vascular niche” in which cells are 
next to endothelial cells [18, 67]. Besides the distinction based on anatomic localization, it has 
been proposed that the endosteal and vascular niche differ functionally with respect to whether 
HSCs are quiescent or actively cycling, respectively [68]. More recent studies using state-of-the-art 
three-dimensional microscopy have challenged the existence of anatomically different niches but 
rather suggested a huge overlap [65, 69]. Notably, this is an active area of research and further 
studies are needed to provide definitive conclusions.  
 
BM microenvironment – Cellular constituents  
Multiple cell types of hematopoietic and non-hematopoietic origin participate in generating a 
supportive BM microenvironment (Figure 3). The evidence suggesting their role in regulating 
various aspects of hematopoiesis will be discussed below. 
 
Non-hematopoietic cell types 
Osteoblasts. The first evidence that osteoblasts regulate HSC function came from in vitro co-
cultures of human CD34+ HSPCs on human osteoblastic cells demonstrating that osteoblasts 
support the growth of HSPCs in short and long-term cultures [70]. Two seminal independent 
studies published in 2003 suggested that osteoblasts critically regulate stem cell function in vivo 
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via Jagged-1 and bone morphogenetic protein (BMP) signaling, respectively [60, 61]. However, 
more recent studies in which two extrinsically-operating factors known to maintain HSCs in vivo, C-
X-C motif chemokine 12 (Cxcl12) and stem cell factor (Scf; also known as Kit ligand, Kitl) were 
conditionally depleted in mature osteoblasts using Bglap-Cre or Col2.3-Cre mice, respectively [71-
73], showed normal BM cellularity and normal blood counts. Importantly, BM cells from these mice 
could still reconstitute lethally-irradiated mice. These data demonstrate that other cells than 
osteoblasts provide CXCL12 and Kitl necessary for HSC maintenance and suggest that 
osteoblasts may be dispensable for HSC maintenance, at least via provision of CXCL12 and Kitl. 
 
Endothelial cells (ECs). With the discovery of the SLAM family markers to increase HSC purity it 
became possible to image HSCs within the BM and to analyze their localization and proximity to 
other cell types. Consequently, it has been shown that 60% of LSK SLAM (LT-HSC) cells were in 
contact with sinusoidal endothelial cells (SECs) [18]. These findings suggested a critical role of 
ECs in the regulation of HSC function which was later substantiated by data revealing that ECs are 
essential for HSC engraftment following chemotherapy- or irradiation-induced myeloablation [74]. 
Moreover, ECs produce several factors that are important for HSC self-renewal and differentiation 
such as Notch ligands and Kitl [73, 75]. In a more recent study, it has been revealed that actively 
cycling HSCs mainly associate with sinusoids while quiescent HSCs reside close to arterioles [68]. 
Collectively, it has become clear that cells of the vasculature are critically involved in the regulation 
of hematopoiesis. 
Perivascular stromal cells. As mentioned above Cxcl12 is an important factor regulating BM 
homing and maintenance of HSCs. Using a Cxcl12-GFP reporter mouse in combination with 
imaging it could be demonstrated that most Cxcl12 is produced by a perivascular, reticular cell 
population termed Cxcl12-abundant reticular (CAR) cells to which 94% of HSCs are in close 
proximity [64]. CAR cells highly express Pdgfrα (CD140a) and Pdgfrβ (CD140b) but lack Sca-1 
expression [76]. Importantly, when CAR cells were depleted from the BM, HSC numbers were 
reduced and HSCs were more quiescent highlighting the critical role of CAR cell-derived CXCL12 
for HSC function [76]. Subsequent studies revealed that CAR cells, together with ECs, are also the 
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major source of Kitl [73, 76]. The Leptin receptor is also a marker for perivascular stromal cells and 
is not expressed by hematopoietic cells, bone-lining cells or endothelial cells [73]. Lepr+ cells also 
express Pdgfrα and Pdgfrβ but not Sca1 and show a high expression of CXCL12 and Kitl and 
therefore highly match originally described CARs [77]. Nestin+ BM cells define another perivascular 
cell type that is in close physical association with HSCs, produces high levels or HSC maintenance 
genes like CXCL12 and Angiopoietin1 (ANG1) and the deletion of Nestin+ cells results in a 
significant reduction in BM HSCs. Moreover, Nestin+ cells behave functionally as MSCs and can 
therefore differentiate into all mesenchymal lineages (osteoblastic, chondogenic and adipogenic) 
and show self-renewal potential expantion in serial transplantations [78]. 
 
Adipocytes. Older studies suggested that adipocytes are rather passive residents of the BM cavity 
[79]. A more recent study, however, compared hematopoiesis from adipocyte-rich vertebrae of the 
mouse tail and adipocyte-free thoracic vertebrae in their composition of hematopoietic cells and 
found that HSPC numbers as well as the CFU activity were reduced in adipocyte-rich BM. Using a 
mouse model in which adipogenesis is inhibited and therefore the mice are adipocyte-free 
revealed that the engraftment of HSCs from adipocyte-free mice was accelerated compared to WT 
controls and the colony forming activity was higher in mice lacking adipocytes [80]. Adipocytes 
were shown to secret factors like neuropillin-1 [81], lipocalin 2 [82, 83], adiponectin [84] and TNF-α 
[85, 86], which can impair haematopoietic proliferation. These data suggest that BM adipocytes act 
predominantly as negative regulators of hematopoiesis [80]. 
 
Nervous system. The BM is not only highly vascularized but also highly innervated by nerves 
from the sympathetic nervous system (SNS) and several lines of evidence demonstrate that the 
SNS is also involved in regulating hematopoiesis. In this light, it has been shown that the egress of 
HSPCs from the BM is dependent on signals from sympathetic nerves that regulate the CXCL12-
CXCR4 interaction [87, 88]. Specifically, Mendez-Ferrer et al. were able to show that circadian 
fluctuations of noradrenaline secretion by SNS neurons activating the β3-adrenergic receptor on 
cells of the BM microenvironment regulates CXCL12 levels which, in turn, regulates BM egress of 
HSPCs [88]. Moreover, Yamazaki et al. [89] showed that transforming growth facor beta (TGF-β) is 
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a quiescence signal originating in the niche that controls HSC dormancy. TGF-β is under most 
conditions inactive (latent TGF-β) and needs to be activated to execute its function. In a 
subsequent study, the same authors elucidated that latent TGF-β is mainly processed into active 
TGF-β in a glial fibrillary acidic protein (GFAP)-expressing cell type. This GFAP-positive cells were 
identified as being nonmyelinating Schwann cells that ensheath sympathetic nerves in the BM and 
were in contact with a considerable proportion of HSCs [90]. 
 
Hematopoietic cell types 
Megakaryocytes. It has been demonstrated that transplanted HSCs lodge close to 
megakaryocytes and that in vitro co-cultures of HSCs and megakaryocytes led to expansion of 
immunophenotypically-defined HSCs [91]. Notably, the expanded HSCs retained their 
reconstitution capacity and multi-lineage potential and the release of IGF-1 and IGFBP-3 from 
megacaryocytes was shown to be responsible for the increased expansion [91]. Later studies also 
showed that HSCs reside in close proximity to megakaryocytes and that the depletion of 
megakaryocytes affects the quiescent state of HSCs. Various soluble factors (Cxcl4, TGF-β1, Tpo) 
were proposed to be responsible for maintaining HSC quiescence [92-94]. 
Macrophages. Winkler et al. have been able to determine a role for BM-resident macrophages as 
important regulators of HSC maintenance via supporting the function of osteolineage niche cells, 
which produce HSC regulating factors such as CXCL12, ANG1 and Kitl. When G-CSF is used to 
mobilize HSCs from the BM to the PB, the number of BM macrophages is reduced leading to the 
suppression of osteolineage cells and subsequently to mobilization of HSCs to the periphery [95]. 
Similarly, Chow et al. showed that the depletion of BM macrophages decreases BM levels of 
CXCL12, leading to HSC egress [96]. 
Osteoclasts. Another class of hematopoietic cells that has become apparent as important niche 
component is bone-resorbing osteoclasts (OCLs) which control B-cell development in the BM by 
regulating the bone microenvironment and the fate of osteoblasts. An impaired activity of OCLs 
leads to decreased expression of CXCL12 and IL-7 in BM cells and a reduction in osteolineage 
cells [97]. Further results showed that ablation of OCLs leads to improper differentiation of 
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osteolineage cells into osteoblasts which impairs HSC homing [98]. 
 
Interleukin-6 
Interleukin-6 (IL-6) is a multifunctional cytokine with various functions in hematopoiesis, the 
immune response and the acute phase response [99-101]. It is well known that IL-6 induces the 
maturation of B-cells into antibody producing plasma cells [102, 103], stimulates the differentiation 
of naïve CD4+ T-cells into effector T-cell subsets [104-106] and is involved in the migration of 
neutrophils to the area of inflammation during the innate immune response [107-110]. 
Using IL-6 knock out mice, it was possible to study the role of IL-6 during steady-state 
Figure 3: The bone marrow microenvironment 
Different cell populations in the BM were reported to contribute to the regulation of hematopoiesis, some 
with a non-hematopoietic and others with a hematopoietic origin. 
Hematopoietic stem cell (HSC), Cxcl12 abundant reticular cell (CAR), Leptin receptor positive cells 
(LepR+), endothelial cell (EC), Pdgrα+Sca1+ mesenchymal stromal cells(PαS MSC), Nestin and 
NG2+ periarteriolar cells (Nes+NG2+) 
22 
 
hematopoiesis as well as inflammation-driven hematopoiesis. While there was no obvious 
regulatory role of IL-6 during steady-state hematopoiesis, IL-6 knock out mice responded 
abnormally to myeloablation and anemia suggesting a role of IL-6 in HSPC proliferation and 
differentiation under regenerative conditions [111, 112]. In this regard, Zhao et al. have recently 
shown that HSPCs are able to directly sense Toll-like receptor (TLR) agonists in vitro, and 
subsequently produce various cytokines including IL-6. Under specific experimental conditions of 
irradiation-induced myeloablation, HSPC-derived IL-6 contributed to hematopoietic recovery in an 
autocrine / paracrine manner [39]. Furthermore, Schürch et al. demonstrated that during viral 
infection, CD8+ cytotoxic T-cells (CTL) release INFγ leading to the production of IL-6 from BM 
MSCs which, in turn, stimulated enhanced monopoiesis [57]. 
Interleukin-6 signaling occurs through the heterotrimeric IL-6 receptor that consists of two 
functional subunits. The IL-6 receptor α chain acts as the ligand-binding subunit but lacks signal-
transducing capacity. It was shown to be expressed on a few cell types, including macrophages, 
neutrophils and some T cell subsets [113-116]. The signal-transducing β subunit, also called 
gp130, is ubiquitously expressed and not only binds IL-6 but is also a receptor subunit for IL11, 
ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), 
cardiotrophin-1 (CT-1), cardiotrophin like cytokine (CLC) and IL-27 [117]. IL-6 first binds the 
membrane-bound IL-6 receptor α subunit (mIL6Rα). Hereafter, the IL-6:IL6-Rα complex binds to 
two molecules of gp130 triggering IL-6 signal transduction and the activation of downstream 
pathways such as the JAK/STAT, the RAS/MAPK or the PI3K pathway [113-116]. This mode of IL-
6R signaling is referred to as cis-signaling. Cells that do not express the IL-6 receptor α subunit but 
only the β subunit are primarily unresponsive to IL-6 [118]. However, the IL-6Rα subunit not only 
exists as membrane-bound version but also in a soluble form (sIL6R). Therefore, IL-6 can bind the 
soluble IL-6 receptor α subunit and the IL6:sIL6Rα complex can then bind to gp130 on any cell, 
activating downstream signaling pathways. This alternative mode of IL-6R signaling is called trans-
signaling [114, 119]. 
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Aims of the study 
As described above, recent studies have unequivocally demonstrated that the BM 
microenvironment plays key roles in regulating physiological steady-state hematopoiesis [18, 60, 
61, 64, 72-78, 80, 87-90]. Furthermore, accumulating evidence suggests that the cellular crosstalk 
between HSPCs and the BM microenvironment in steady-state as well as during infection- and 
inflammation-driven hematopoiesis may be more complex than currently appreciated. Therefore, 
the principal goal of my PhD thesis was to get a deeper insight into the complex interactions 
between the hematopoietic system and its supportive microenvironment in steady-state and during 
demand-adapted hematopoiesis. To achieve this, I also wanted to better characterize the different 
celullar components of the BM microenvironment.  
 
Aim 1: To identify potential regulators of infection- and inflammation-driven hematopoiesis 
produced by non-hematopoietic cells of the BM microenvironment. 
We set out to investigate how the BM microenvironment supports the hematopoietic system in 
adaptation to inflammation. To this end, WT mice were stimulated with LPS or poly(I:C) to mimic 
gram-negative bacterial or viral infection, respectively. Different immunophenotypically defined 
non-hematopoietic BM cells were sorted using flow cytometry and differential gene expressions 
among these cells were examined using microarray analysis. This investigation revealed IL-6 as 
potential regulator of hematopoiesis during inflammation, and thus, IL-6 was chosen for further 
validation (see also Aim 3). 
 
Aim 2: To optimize the characterization and isolation of non-hematopoietic cells of the BM 
microenvironment to assess global molecular signatures during development, 
aging and inflammation. 
In addition to study the regulatory role of the BM microenvironment during inflammation-driven 
hematopoiesis we also wanted to study its role during aging and development of the hematopoietic 
system. This work is done in collaboration with Patrick Helbling from the group of Prof. Dr. Cesar 
Nombela-Arrieta. To obtain gene expression profiles of non-hematopoietic BM cells of these 
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different conditions, we planned to perform RNA sequencing for which high amounts of good 
quality RNA are required. Therefore, we first optimized the methods of isolation and preparation of 
the different non-hematopoietic cell types as well as advanced the characterization of 
immunophenotypes of BM microenvironment cell subsets. We are currently using the newly 
established protocol to isolate BM microenvironment cell types of LPS or poly(I:C) treated WT mice 
as well as of young and aged mice. Gene expression profiles of these cells will be determined 
using RNA sequencing. The newly established protocol for the isolation of cells of the BM 
microenvironment was also applied in aim 3. 
 
Aim 3: To validate regulators of inflammation-driven hematopoiesis provided by non-
hematopoietic cell types of the BM microenvironment. (Research article) 
Having obtained evidence for IL-6 production by non-hematopoietic BM stromal cells in our initial 
microarray analysis we set out to confirm and potentially extend these findings. Thus, we treated 
WT animals with LPS or poly (I:C) to mimic gram-negative bacterial or viral infection, respectively. 
Different non-hematopoietic cell types of the BM microenvironment were flow cytometrically sorted 
according to our newly established protocols (aim 2). I then determined gene expression for a 
selection of candidate hematopoietic growth factors and inflammatory cytokines by using qPCR. In 
line with the previous microarray data, we could independently confirm inducible Il6 expression in 
non-hematopoietic BM stromal cells. Consequently, we chose to further investigate the regulatory 
role of IL-6 on hematopoiesis during infection- and inflammation-driven hematopoiesis using a 
variety of experimental approaches.  
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Results I 
Identification of potential regulators of hematopoiesis during inflammation 
In order to get a deeper insight into the interactions between the hematopoietic system and its BM 
microenvironment during inflammation-adapted heamtopoiesis, we treated WT mice with PBS as 
control or with LPS or poly(I:C) to mimic gram-negative bacterial or viral infection, respectively. We 
then prospectively isolated different non-hematopoietic BM cell types according to their expression 
of the cell surface markers CD45, Ter119, Sca-1, CD31 and CD140b using flow cytometry. First, 
non-hematopoetic cells were defined by the absence of the expression of CD45 and Ter119 
(CD45-Ter119-) and endothelial cellls could be defined by their expression of CD31 (CD45-Ter119-
CD31+). Based on the differential expression of CD140b along with Sca-1 it is possible to 
distinguish MSCs (CD45-Ter119-CD31-CD140b+Sca-1+) [120], CARs (CD45-Ter119-CD31-
CD140b+Sca-1-) [55, 76] and a pupulation which is not further defined within the remaining CD45-
Ter119-CD31- non-hematopoietic cells and therefore was called unknown (CD45-Ter119-CD31-
CD140b-Sca-1-) (Figure 4). RNA was extracted and cDNA synthesized from these cell populations 
followed by gene expression analysis using microarray analysis(Figure 5). Subsequently, we 
determined differential expression of genes between the three different conditions (PBS control, 
LPS and poly(I:C)) (fold change higher than 1.5, p-value lower than 0.5, signal intensity higher than 
3). We mainly focused on uniquely, differentially expressed genes upon stimulation and some 
genes were identified as potential regulatory genes of inflammation-driven hematopoiesis due to 
their differential expression (Figure 6). Among these genes Il6 showed one of the highest up-
regulations among all examined genes. Il6 upregulation was only detectable during LPS treatment 
and specifically in CAR cells which could be confirmed using qPCR (Figure 7). Therefore, IL-6 was 
chosen for further functional validation of its putative regulatory role during inflammation-driven 
hematopoiesis. All further data related to IL-6 are described in the “Resarch Article” section. 
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Figure 5: Project overview Microarray. 
Non-hematopoietic BM cells of PBS, LPS or poly(I:C) injected WT mice were flow-cytometrically sorted, their RNA 
extracted and cDNA synthesized. The cDNA was then analysed using a microarray chip and differential gene 
expressions were examined. 
Figure 4: Representative FACS profile of the gating strategy of ECs, MSCs, CARs and 
Unkn. 
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Figure 6: Data analysis of unique differentially expressed genes upon stimulation. 
Gene expressions were compared between different treatment groups. Here an example is shown of 
genes that were differentially expressed between PBS and LPS-treated WT mice. We mainly focused 
on genes that were differentially expressed in one of the four analyzed cell populations. 
Figure 7: qPCR validation of the differential expression profile of Il6. 
Examining gene expression profiles, we found a high upregulation of Il6 and this specifically in CAR cells 
during LPS treatment. This could be confirmed using qPCR. 
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Changes in gene expression profiles of non-hematopoietic cells of the BM 
microenvironment during inflammation, development and aging 
Based on the microarray analysis of non-hematopoietic BM cell subsets from LPS- or poly(I:C)-
stimulated WT mice, we were able to study gene expression changes among these various 
populations in comparison to the steady-state situation, in order to identify potential regulators of 
inflammation-driven hematopoiesis. In addition, the group of Prof. Dr. Cesar Nombela-Arrieta 
followed the idea of analyzing gene expression changes of non-hematopoietic BM cells of young 
mice (15 – 18 days) compared to aged animals (more than 2 years). Therefore, we decided to 
collaborate and combine the two projects and investigate the gene expression changes of non-
hematopoietic BM cells during the development of a mouse from short after birth over adulthood 
towards old age as well as during LPS and poly(I:C) treatment, simulating gram-negative bacterial 
and viral infection. We decided to analyze the gene expression changes using RNA sequencing, 
as this technique allows the unbiased detection of novel transcripts, whereas with microarray only 
known genes can be analyzed. Therefore, we decided to repeat the gene expression analysis of 
non-hematopoietic BM cells during LPS and poly(I:C) stimulation and used this opportunity to 
further optimize the characterization and isolation of non-hematopoietic BM cells to potentially get 
expression profiles of more refined cell populations (Figure 8). 
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Figure 8: Project overview RNA sequencing.  
BM of young, old and adult animals as well as of LPS or poly (I:C) treated adult mice will be processed. Different non-
hematopoietic cell types will be sorted, their RNA extracted and gene expressions analyzed using RNA sequencing. 
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Characterization and isolation of non-hematopoietic BM cells 
As we would need a higher amount of RNA for RNA sequencing as for the microarray analysis, we 
tried to improve our isolation protocol in order to extract higher cell numbers. We tested if 
mechanical treatment by crushing bones with a mortar and pestle would help to extract more cells 
from the bone, as this method was described before [120, 121]. However, we observed that 
crushing the bones in addition to just cutting them into small pieces led to suboptimal recovery of 
MSCs and CARs, hence we continued only cutting the bones (Figure 9). Given the non-
hematopoietic cell populations only make up around 0.1-0.8% of the whole BM we decided to test 
enrichment methods. We compared two commercially available magnetic bead-based enrichment 
methods (MACS from Miltenyi Biotec and Easy Sep from Stemcell Technologies). Our findings 
revealed that the enrichment and consequently overall yield for the CD45/Ter119 negative fraction 
with the MACS columns was much higher than with Easy Sep method (Figure 10).  
Using high-end imaging technologies it is possible to distinguish arteriolar and sinusoidal 
endothelial cells (AECs and SECs) within the EC population using the sinusoidal marker CD105, 
also called endoglin [122]. Therefore, we tested whether inclusion of CD105 into our FACS 
analysis would allow flow-cytometrically separation of AECs and SECs. Indeed, after gating on 
CD31+ ECs we could distinguish two populations by gating on CD105high and CD105low expressing 
cells (Figure 11). Hence, our refined FACS strategy makes it possible to sort five non-
hematopoietic BM cell populations including AECs, SEC, MSCs, CARs and Unkn (Figure. 12). 
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Figure 9: Representative FACS profile of Sca1+CD140b+ MSCs and Sca1-CD140b+ CARs after processing 
bones with or without crushing of bones (pregated CD45-Ter119-CD31-)  
Figure 10: Representative FACS profile of the gating strategy of ECs, MSCs, CARs and Unkn without enrichment or 
using EaysSep or MACS columns. 
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Figure 12: Representative FACS profile of the gating strategy of AECs, SECs, MSCs, CARs and Unkn. 
Figure 11: Representative FACS profile of the subdivision of AECs and SECs within CD31+ endothelial cells 
(pregated CD45-Ter119-). 
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Sorting of non-hematopoietic BM cells followed by RNA extraction 
Given the relatively low frequency of non-hematopoietic BM stromal cells we first wanted to test 
whether it is feasible to purify enough RNA to subsequently perform standard library preparation 
without first having to amplify the RNA that inheres the potential disadvantage of leading to a 
biased representation of transcripts. In general, a total of 100 ng RNA per cell population is 
required to perform standard library preparation. Since a single cell usually contains 6-30 pg RNA, 
3’300 – 16’600 non-hematopoietic BM cells per population would need to be isolated which could 
only be achieved by pooling mice for each condition. To test if this approach is feasible, we 
performed a pilot study to establish a protocol for RNA purification from limiting cell numbers. To 
this end, we first sorted splenocytes as there are abundant numbers contained in one mouse. We 
sorted different cell numbers and extracted the RNA from the samples using two different 
commercially available RNA extraction kits (RNeasy Micro and RNeasy Micro Plus). We observed 
better performance with the RNeasy Micro Plus Kit. However, total RNA amounts were 
considerably lower than predicted (Fig. 13) necessitating the use of amplification methods along 
with the library preparation. Accordingly, we decided to use the “Clonetech SMRTer Stranded totat 
RNA-Seq Kit for Pico Input Mammalian Total RNA” to prepare the RNA Seq library. 
 
  
Figure 13: RNA amounts extracted from determined numbers of splenocytes with the RNeasy Micro or the RNeasy 
Micro Plus Kit and the cell numbers necessary to reach 100ng of RNA. 
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RNA Sequencing 
In a first attempt to analyze the quality and quantity of sorted RNA for RNA sequencing, we 
injected one cohort of WT mice with PBS, LPS or poly(I:C). We sorted AECs, SECs, MSCs, CARs 
and Unkn from these different treatment groups and extracted their RNA using the commercially 
available RNeasy Micro Plus Kit. We measured RNA quantity and analyzed RNA quality by 
examining their RIN values. As quality and quantity of the total input RNA were suitable we used 
600 pg of total input RNA of each sample to prepare an RNA seq library using the Clonetech kit for 
low input RNA. This kit includes cDNA synthesis of total input RNA followed by ribosomal cDNA 
depletion and PCR amplification of the low amount of input material. Subsequently, the library was 
sequenced and Patrick Helbling of the Nombela-Arrieta group and myself carried out quality 
controls. In order to test the accuracy of our flow-cytometry-based method for the isolation of non-
hematopoietic BM stromal cell subsets, we analyzed expression levels of the sorting markers 
CD45, Sca1, CD105 and CD140b in the sorted populations, which showed the expected 
expression pattern (Figure 14A). In addition, we also analyzed the expression levels of different 
housekeeping genes to see if they are evenly expressed among all cell types in all conditions 
(Figure 14B). We also analyzed expression of Kitl and Cxcl12, as these genes show specifically 
restricted expression in ECs and CARs during steady-state hematopoiesis [64, 72, 73]. These 
expected expression patterns could be confirmed (Figure 14C). Moreover, we performed a 
principle component analysis (PCA) and created a dendrogram to investigate clustering of the 
different samples. These methods showed that samples of the same cell type of different 
conditions clustered as expected with the exception of AECs and SECs, which did not cluster 
independently (Fig. 15). This problem might arise from the fact that Sca-1 is an IFN-inducible gene 
and is up-regulated upon activation due to inflammation. Therefore, we will have to be more 
restricted in our gating of AECs and SECs for their flow-cytometrical sorting. However, another 
explanation could be that AECs and SECs are simply not so different form each other. In general, 
the RNA sequencing data gives us promising results and the confidence that the newly established 
protocol provides enough RNA with a good quality for RNA sequencing. 
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Figure 14: A) Normalized counts from RNA sequencing data of phenotypical markers of non-hematopoietic BM cell 
types, which were used for the prospective isolation of these cell types. In addition, the same normalized counts from 
RNA sequencing data are shown for B) some housekeeping genes and for C) Kitl and Cxcl12. 
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Figure 15: Principal component analysis and dendrogram of all analyzed genes, showing the dissimilarities of the 
non-hematopoietic BM cell subsets. 
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Abstract 
Hematopoiesis is maintained by hematopoietic stem and progenitor cells (HSPCs) that are located 
in the bone marrow (BM) where they are embedded within a complex supportive 
microenvironment. The BM microenvironment not only regulates steady-state hematopoiesis but is 
also an emerging key player during emergency hematopoiesis. Through a combination of gene 
expression analyses in prospectively isolated non-hematopoietic BM cell populations and various 
mouse models we have revealed that BM CXCL12-abundant reticular (CAR) cells are a major 
source of systemic and local BM IL-6 levels following LPS stimulation. Importantly, while IL-6 is 
dispensable during the initial phase of LPS-induced emergency hematopoiesis, it is required to 
sustain emergency hematopoiesis during chronic-repetitive inflammation. Our data highlight the 
essential role of the non-hematopoietic BM microenvironment for the sensing and integration of 
pathogen-derived signals into sustained hematopoietic responses.  
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Introduction 
The hematopoietic system is hierarchically organized and maintained by hematopoietic stem cells 
(HSCs) that give rise to highly-proliferative but increasingly lineage-committed hematopoietic 
progenitor cells (HPCs) which will eventually differentiate into all mature blood cell types [123]. 
This special functional architecture ensures massive cell amplification thereby accounting for the 
enormous cellular demand during steady-state hematopoiesis due to the short-lived nature of the 
vast majority of mature blood cells. It is estimated that approximately 0.5 - 1 x 1011 granulocytes 
are being generated per day during steady-state conditions in an adult human individual [1] 
(Nombela-Arrieta & Manz, 2017, accepted). Such remarkable proliferative and differentiation 
capacity requires intricate regulation as dysregulated hematopoiesis can lead to the inability to 
sustain life-long blood formation (bone marrow failure), and can cause disturbed differentiation 
(myelodysplasia) as well as excessive blood cell production (leukemia) [7-13]. 
The multifaceted nature of hematopoietic regulation is best studied for HSCs, in which a 
plethora of cell-autonomous regulatory mechanisms such as preferential use of specific DNA 
repair pathways and of particular metabolic pathways govern HSC self-renewal [124-126]. In 
addition, it has become increasingly evident over the past 15 years, that HSC-non-autonomous 
regulatory pathways operating within the bone marrow (BM) microenvironment and delivering 
regulatory signals to HSCs are essential to maintain HSC function throughout life [127]. The BM 
microenvironment consists of various mostly non-hematopoietic cell types including osteoblasts 
[60, 61], mesenchymal stromal cells [78], CXCL12-abundant reticular [64, 76] and perivascular 
stromal cells [72, 73], and endothelial cells [73-75, 128]. In addition adipocytes, sympathetic 
nerves, non-myelinating Schwann cells and also some hematopoietic cell types such as 
macrophages and megakaryocytes have been shown to be part of the supportive BM 
microenvironment [80, 87, 88, 90, 92-96]. 
Various naturally-occurring stimuli, most importantly bleeding and infection, have shaped 
the hematopoietic system during evolution to be able to rapidly augment its cellular output to meet 
the enormous demand for mature blood cells during these emergency situations [2, 4]. How 
infection- and inflammation-driven emergency hematopoiesis is regulated, is an active area of 
research and we have recently reviewed well-established and newer concepts around this theme 
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[5]. An emerging concept is that the BM microenvironment participates in regulating the switch 
from steady-state to emergency hematopoiesis. For example, we have recently shown that Toll-
like receptor (TLR)-expressing endothelial cells sense pathogen-derived lipopolysaccharide (LPS) 
and translate the presence of gram-negative bacteria into emergency granulopoiesis via secretion 
of granulocyte colony-stimulating factor (G-CSF) [56]. However, the regulation of inflammation-
driven demand-adapted hematopoiesis and the involvement of the BM microenvironment remain 
incompletely understood. Therefore, we have undertaken a systematic approach to gain a deeper 
understanding of how the non-hematopoietic BM microenvironment regulates the hematopoietic 
system’s adaptation to severe infection with the goal to increase cellular output to meet the higher 
demand for mature myeloid cells. To this end, we performed gene expression analyses on 
prospectively isolated non-hematopoietic BM cells from LPS- and poly(I:C)-treated mice to mimic 
gram-negative and viral infection, respectively and found that Interleukin-6 (IL-6) is significantly 
and specifically up-regulated in CXCL12-abundant reticular (CAR) cells. Moreover, systemic and 
local BM IL-6 level largely depend on IL-6 production by CAR cells. Functional analyses using a 
variety of genetic mouse models elucidated that, although IL-6 is dispensable for a proper 
response during short-term LPS stimulation, IL-6 is critical to sustain emergency hematopoiesis 
during chronic-repetitive LPS-induced inflammation. Our results reveal a previously 
underappreciated regulatory role of the BM microenvironment as a central hub that controls the 
switch from steady-state to emergency hematopoiesis by virtue of its ability to sense systemically 
disseminated pathogens followed by the allocation of essential hematopoietic growth factors.  
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Material and Methods 
Mice and generation of reciprocal chimeras 
Mice used in this study included C57BL/6J (CD45.2+), B6.SJL (CD45.1+), Tlr4-/- (CD45.1+ and 
CD45.2+), Rag1-/- (B6;129S7-Rag1<tm1Mom>/J), Il6-/- (B6.129S2-Il6tm1Kopf/J) [111], Lepr-cre 
[129], Il6flox/flox [130] and loxP-GFP mice (B6.Cg-Gt(ROSA) 26Sor tm6(CAGZsGreen1)Hze/J). The 
Il6flox/flox mice were kindly provided by Dr. J. Hidalgo (Universitat Autònoma de Barcelona), Tlr4-/- 
were kindly provided by Dr. Shizuo Akira (Osaka University) and C57BL/6J (CD45.2+) and B6.SJL 
(CD45.1+) were obtained from Jackson Laboratories. Wt (CD45.1+ and CD45.2+), Il6-/- and Tlr4−/− 
(CD45.1+ and CD45.2+) mice were used to generate reciprocal chimeras. Mice were lethally 
irradiated with 950 cGy and transplanted intravenously with 5 × 106 total BM cells. All animals were 
maintained at the University Hospital Zurich animal facility and treated in accordance with 
guidelines of the Swiss Federal Veterinary Office. Experiments and procedures were approved by 
the Veterinäramt des Kantons Zurich, Switzerland. 
 
LPS and pIC injections 
In the short-term LPS induced inflammation studies, mice received 2 intraperitoneal injections of 
35 µg ultrapure LPS from E. coli 0111:B4 (InvivoGen) 48 hours apart and were analyzed 24 hours 
after the last injection. For the long-term LPS induced inflammation studies, mice received 9 
intraperitoneal injections of 35 µg ultrapure LPS from E. coli 0111:B4 (InvivoGen) over a periode of 
3 weeks (day 0, 2, 4, 7, 9, 11, 14, 16, 18) and were analyzed 24 hours after the last injection (day 
19). For some experiments, mice were injected once with 35 µg LPS or with 100 ug pIC 
(InvivoGen) and analyzed 4 hours later. 
 
Flow cytometry 
The following antibodies (all from eBiosciences, unless otherwice stated) were used to assess 
mature BM cell populations: anti-CD11b (M1/70), anti-Gr1 (RB6-8C5). anti-CD45.1 (A20, 
Biolegend) and anti CD45.2 (104) were used to analyze chimerism of reciprocal BM chimeric mice. 
To analyze HSPCs, the following antibodies were used; anti-CD3ɛ (145-2C11), anti-CD4 (GK1.5, 
Biolegend), andi-CD8α (53-6.7, BIolegend), anti-B220 (RA3-6B2), anti CD11b (M1/70), anti-Gr1 
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(RB6-8C5), anti-Ter119 (TER-119, Biolegend), anti-IL7Rα (A7R34), anti-NK1.1 (PK136, 
Biolegend), anti-Streptavidin Pacific Blue (Life Technologies), anti-cKit (2B8), anti-Sca-1 (D7, 
Biolegend), anti-CD34 (RAM34), anti-FcgR (93), anti-CD48 (HM48-1), anti-CD150 (TC15-12F12.2, 
Biolegend).  
Classical and plasmacytoid dendritic cells were stained using anti-CD3e (145-2C11), anti-CD19 
(MB19-1), anti-NK1.1 (PK136; Becton Dickinson), anti-CD45RA (14.8; BD Biosciences), anti-
CD11c (N418), and anti-MHCII (M5/114.15.2).  
Also used to sort different non-hematopoietic BM stromal cells were anti-Sca1 (D7, Biolegend), 
anti-Ter119 (TER-119, Biolegend), anti-CD45 (30-F11, Biolegend), anti-CD31 (390), anti-CD105 
(MJ7/18), and anti-CD140b (APB5). To stain the Il6 receptor α and β subunits anti-CD126 
(D7715A7, Biolegend)and anti-CD130 (KGP130) were used. 
 
Processing of bones 
Femurs, tibias and hip bones were removed, BM was flushed and cells were resuspended with 
digestion medium (DMEM/10% FCS/10mM HEPES/0.4% collagenase II (Worthington)/0.02% 
DNase I (Worthington)). Bones were cut into small pieces and combined with flushed BM in a total 
of 5 ml digestion medium. Bones and BM were incubated for 45 min at 37°C on a shaker and 
afterwards the cell suspension was filtered through a 70um cell strainer. LS MACS columns 
(Miltenyi Biotec) were then used to enrich the cell suspension for CD45-Ter119- cells following the 
supplier’s protocols. 
 
Colony-forming unit (CFU) assay  
1x104 red blood cell lysed whole BM cells of 3 week PBS or LPS treated mice were used. Cells 
were plated in a mix of methylcellulose (Methocult M3234; StemCell Technologies), Iscove’s 
modified Dulbecco’s medium (30% fetal calf serum, 2 mM L-glutamine, 50 mM 2-mercaptoethanol) 
and the following factors: mIL3 (10 ng/mL), hIL6 (10 ng/mL), mSCF (10 ng/mL), mGM-CSF (10 
ng/mL), mTPO (10 ng/mL), mFLT3-Ligand (10 ng/mL) (all Pepro Tech), and hEPO (10 Ug/mL). 
Colonies were counted and classified after 12 days of in vitro culture.  
For the serial replating of cKit enriched WT cells, LS MACS columns (Miltenyi Biotec) were used 
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for the enrichment. Cells were then plated in the same mixture of methylcellulose and cytokines as 
mentioned above. The only exception was that once hIL6 was added to the culture and once not. 
After 7 days of culture, colonies were counted and classified and the cells were resuspended using 
37°C warm PBS and replated at the same conditions as before. 
 
RNA extraction and cDNA synthesis 
AEC, SEC, MSC and CAR populations were sorted directly into RLT Lysis Buffer provided by 
Qiagen (RNeasy Micro Plus Kit). Organs were removed and 30 µg per organ were snap frozen in 
liquid nitrogen. Using mortar, pistil and liquid nitrogen, organs were pulverized and transferred to 
RLT lysis Buffer of the RNeasy Mini Plus Kit (Qiagen). RNA was extracted following the suppliers 
protocols followed by cDNA synthesis using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). 
 
Quantitative reverse-transcription PCR  
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using SYBR green 
reagent (Applied Biosystems). Samples were run on a 7500 FAST real-time PCR thermal cycler 
(Applied Biosystems) using Gapdh as housekeeping gene to normalize the RNA content of 
samples.  
 
Enzyme-linked immunosorbent assay (ELISA) 
Plasma samples were obtained by postmortem cardiac puncture. Blood samples were centrifuged 
and the supernatant was used for further procedures. BM samples were generated flushing one 
femur with a 1:1 mix of cOmplete ULTRA Tablets (Roche) dissolved in PBS and RayBio 2x Cell 
Lysis Buffer (Rybiotech, Inc.). IL-6 Protein levels were measured using an ELISA Kit (R&D) 
following the suppliers Protocol. 
 
Equations and statistical analyses  
Significance of differences was analyzed using Student t test. A difference between experimental 
groups was considered significant when the P value was 0.05. All statistical analyses were 
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calculated with Prism software (GraphPad Software, version 5).  
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Gene Forward Reverse 
Cxcl12 GCATCAGTGACGGTAAACCA GTTTAAAGCTTTCTCCAGGTACTC 
Flt3l AGTTCTGCTTCTCAGTCAGG TTAGATATGCTGTACCCATCCTC 
Csf3 GCTTCCTGCTTAAGTCCCTG CTTAGGCACTGTGTCTGCTG 
Csf2 CCTGTCACGTTGAATGAAGAG TTGAGTTTGGTGAAATTGCCC 
Il1a CAACGGGAAGATTCTGAAGAAGAG GGTTGGATGGTCTCTTCCAG 
Il1b TCTTTGAAGAAGAGCCCATCC GTTGTTCATCTCGGAGCCTG 
Il3 AGCTCCCAGAACCTGAACTC ACTTCTCCTTGGCTTTCCAC 
Il6 CTCTGCAAGAGACTTCCATCC CGACTTGTGAAGTGGTATAGAC 
Infa GGACTTTGGATTCCCGCAGGAGAAC GCTGCATCAGACAGCCTTGCAGGTC 
Infb AACCTCACCTACAGGGCGGACTTCA TCCCACGTCAATCTTTCCTCTTGCTTT 
Kitl CAGAAACTAGATCCTTTACTCCTG ACACTGACTCTGGAATCTTTCTC 
Tlr1 CCTACAGAAACGTCCTATACCCA CAGTAGAAGATGAGGGAATTTGGT 
Tlr2 TCAGACAAAGCGTCAAATCTCAG GCATCACATGACAGAGACTCC 
Tlr3 GATAAAGCGAGTTTCACTTTCAGG CAGATAGAGAACAGGTGCGT 
Tlr4 CCAATGCATGGATCAGAAACTC ATTTCACACCTGGATAAATCCAGC 
Tlr5 ACACTTCAGCAGGATCATGG ATAGTTGAAGCTGAGCAGGAG 
Tlr6 AGGAAGTCTTGGTAAGTAAGAAGG ATCCAAGCTCTATTTCCAGCAC 
Tlr7 TTCAAGAAAGATGTCCTTGGCTC AAATTTGTCTCTTCCGTGTCCA 
Tlr8 CCTTCCTTTGTCTATAGAACATGG ATGTGTAATGGCATTGTCTGAC 
Tlr9 CCCAACATGGTTCTCCGTC TCAGCTCACAGGGTAGGA 
Tnf CACGTCGTAGCAAACCACCAAGTGGA TGGGAGTAGACAAGGTACAACCC 
Tpo GAACCCAGCTTCCTCTACAG TGGGAACTTGTTTAGTGTGAGG 
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Results 
Il6 expression is significantly and specifically induced in BM CAR cells upon a single LPS 
injection 
In order to investigate mechanisms by which the non-hematopoietic BM microenvironment 
regulates the hematopoietic system’s adaptation to severe systemic infection we modified a 
previously published method [120] to prospectively isolate different non-hematopoietic BM stromal 
cell populations by FACS. Based on expression of CD45 and Ter119 to exclude hematopoietic 
cells in conjunction with Sca-1, CD31, CD105 and CD140b, it was possible to flow-cytometrically 
define and isolate several non-hematopoietic cell types from mouse BM (Figure 1A). CD45-Ter119-
CD31+ endothelial cells, by virtue of their differential expression of Sca-1 and CD105 (endoglin), 
could be further delineated into sinusoidal endothelial cells (SECs, CD45-Ter119-
CD31+CD105hiSca-1int) and arteriolar endothelial cells (AECs, CD45-Ter119-CD31+CD105intSca-
1hi). The remaining CD45-Ter119-CD31- non-endothelial cells can be divided into the following 
three cell populations based on their CD140b (PDGFRβ) and Sca-1 expression: CD45-Ter119-
CD31-Sca1+CD140b+ and CD45-Ter119-CD31-Sca1-CD140b+ cells which are highly enriched for 
mesenchymal stromal cells (MSCs) and CXCL12-abundant reticular (CAR) cells, respectively [76, 
120]. The quintuple-negative (CD45-Ter119-CD31-Sca1-CD140b-) population mostly consisted of 
debris as determined by morphological assessment of cytospin preparations and corroborated by 
the consistent failure to isolate RNA for expression analysis from this population (Figure 1A and 
data not shown). We therefore excluded this population from further analyses.   
Having established this FACS-based prospective isolation methodology, wild-type (WT) 
mice received a single injection of high-dose lipopolysaccharide (LPS) or polyinosinic-polycytidylic 
acid (poly(I:C)) to mimic severe gram-negative or viral infection, respectively. Four hours after LPS 
or poly(I:C) injection, treated and PBS-injected control mice were sacrificed, the different non-
hematopoietic cell populations were isolated by flow-cytometry and subjected to gene expression 
analysis by RT-qPCR for a selection of candidate hematopoietic growth factors and inflammatory 
cytokines (Figure 1B). Expression values relative to Gapdh were visualized as a heat map (Figure 
1C) to better account for the huge range of expression values between weakly and strongly 
expressed genes. These experiments yielded several interesting pieces of information. First, most 
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of the assessed genes were neither relevantly expressed in PBS-injected, i.e. unperturbed steady-
state hematopoiesis nor induced following LPS or poly(I:C) treatment. Second, in accordance with 
previously published data [73] steady-state Kitl (also known as stem cell factor, Scf) expression, 
although relatively weak, was specifically confined to AECs and CAR cells thereby confirming our 
prospective isolation strategy. Third, these results also confirmed and extend our previously 
published findings on Csf3 (also known as granulocyte colony-stimulating factor, Gcsf) expression 
in endothelial cells upon LPS stimulation [56] by demonstrating that LPS-induced Csf3 expression 
is largely restricted to AECs but not SECs. Most importantly however, among all assessed genes, 
Il6 demonstrated the most remarkable expression pattern. While Il6 was undetectable in steady 
state, it was highly significantly and quite specifically up-regulated in CAR cells following LPS but 
not poly(I:C) stimulation, and it also showed the highest expression compared to the other genes. 
To further investigate whether CD45-Ter119-CD31-Sca1-CD140b+ cells are indeed highly enriched 
for CAR cells that are defined by their abundance for CXCL12 we independently assessed Cxcl12 
expression within the four different immunophenotypically-defined non-hematopoietic BM cell 
populations. As expected we observed extremely high Cxcl12 expression in CD45-Ter119-CD31-
Sca1-CD140b+ cells (Figure S1A) which is compatible with the notion that this immunophenotype is 
able to define CAR cells [76]. 
In light of the above results, we focused our further efforts on studying the role of CAR cells 
as a potential relevant, previously unknown source of IL-6 during LPS-induced inflammation.  
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Figure 1. Expression of hematopoietic growth factors and inflammatory cytokines in non-
hematopoietic BM stromal cell subpopulations following a single LPS injection. 
(A) Representative FACS profiles showing non-hematopoietic cell types of the BM 
microenvironment either non-depleted (upper panel) or with MACS column-based CD45/Ter119 
depletion (lower panel). AEC, arteriolar endothelial cells; SEC, sinusoidal endothelial cells; MSC, 
mesenchymal stromal cells; CAR cells, CXCL12-abundant reticular cells. (B) Graphical scheme 
depicting experimental outline for the induction of LPS- or poly(I:C)-induced inflammation and 
subsequent isolation of non-hematopoietic BM cells. (C) Gene expression of 12 hematopoietic 
growth factors and inflammatory cytokines from PBS-, LPS- or poly(I:C)-injected WT mice. Relative 
expression normalized to Gapdh from RT-qPCR is depicted as a heat map. Kitl, kit ligand, Flt3l, 
FMS-like tyrosine kinase 3 ligand; Thpo, thrombopoietin; Csf2, colony stimulating factor 2 
(granulocyte-macrophage); Csf3, colony stimulating factor 3 (granulocyte); Tnf, tumor necrosis 
factor; Il1a, interleukin 1 alpha; Il1b, interleukin 1 beta; Il3, interleukin 3; Il6, interleukin 6; Ifna, 
interferon alpha; Ifnb, interferon beta.  
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Supplemental Figure 1. Cxcl12 expression in different flow-cytometrically isolated non-
hematopoietic BM cells. 
(A) Cxcl12 expression levels in BM AECs (white bar), SECs (yellow bar), MSCs (red bar) and CAR 
cells (grey bars) were assessed by RT-qPCR and normalized to house-keeping gene Gapdh. 
Results from three different experiments are shown. 
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CAR cells are the major source for systemic and local BM IL-6 levels upon LPS-induced 
inflammation 
 As an initial approach to reveal the relative contribution of CAR cells to IL-6 abundance 
following LPS-induced inflammation, we assessed Il6 expression in total tissue extracts from major 
solid organs (heart, lung, liver, kidney, spleen) as well as total bone upon LPS stimulation. To this 
end, we injected WT mice with a single high-dose of LPS, sacrificed mice 4 hours later, isolated 
and homogenized tissues, and assessed Il6 transcripts by RT-qPCR in comparison to PBS-
injected control mice (Figure 2A). We chose this particular time point after a single high-dose of 
LPS for our initial analyses as plasma and BM IL-6 levels peaked at 4 hours post injection and 
rapidly returned to undetectable levels thereafter (Figure S2A and B). While Il6 expression was 
undetectable in control mice, it was induced in all organs analyzed, albeit to a very different extent. 
Of note, inducible Il6 expression was significantly highest in total bone as compared to all other 
organs. Spleen and lung had also relatively high Il6 expression, whereas kidney, heart, and liver 
showed a minor Il6 induction following LPS treatment (Figure 2B). These results strongly suggest 
that total bone consisting of both hematopoietic as well as non-hematopoietic cells is indeed a 
relevant source of IL-6 upon LPS-induced inflammation.  
A common assumption infers that hematopoietic cells especially monocytes and tissue-
resident macrophages are major sources of inflammatory cytokines. Moreover, a recently 
published study demonstrated that HSPCs are able to directly sense TLR agonist such as LPS and 
respond by secretion of inflammatory cytokines including IL-6, which, in turn, contributes to 
emergency hematopoiesis in an autocrine / paracrine manner albeit under very specific 
experimental conditions [39]. In order to dissect the relative importance of hematopoietic versus 
non-hematopoietic cells to IL-6 availability, we generated reciprocal BM chimeric mice with Il6 
expression restricted to either hematopoietic (WT ⇒ Il6-/-) or non-hematopoietic cells (Il6-/- ⇒ WT) 
as well as control mice (WT ⇒ WT and Il6-/- ⇒ Il6-/-) and assessed systemic and local IL-6 levels in 
their plasma and BM lysates following PBS or high-dose LPS treatment by ELISA (Figure 2A). We 
observed a strikingly clear pattern of highly and equally elevated plasma and BM IL-6 levels in 
LPS-treated WT ⇒ WT and Il6-/- ⇒ WT mice. By contrast, Il6-/- ⇒ Il6-/- and WT ⇒ Il6-/- mice were 
non- or severely hypo-responsive towards LPS stimulation in terms of elevation of IL-6 levels in 
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plasma and BM lysates (Figure 2C). Given the reported relative resistance to gamma-irradiation of 
tissue-resident macrophages, we have previously analyzed macrophage chimerisms in various 
organs of reciprocal BM chimeric mice 4 months after lethal irradiation and BM transplantation but 
found, with the exception of liver macrophages, negligible persistence of host-derived macrophage 
(<1%) [46]. Therefore, taking its limitations into account, BM chimeric mice are undoubtedly a 
valuable and well-suited experimental tool to generally address the question as to whether 
hematopoietic or non-hematopoietic cells contribute to a given phenotype. Furthermore, it has 
recently been shown that CD8+ cytotoxic T cells stimulate IL-6 release from BM MSCs in an 
Interferon-dependent manner during viral infection [57]. To assess the role of T cells for IL-6 
induction in the setting of LPS-induced inflammation, we also stimulated T cell-deficient Rag1-/- 
mice with high-doses of LPS and measured systemic and local BM IL-6 levels by ELISA which 
were indistinguishable between WT and Rag1-/- mice (Figure 2D). Thus, our data unambiguously 
demonstrates that T lymphocytes are dispensable for IL-6 induction following LPS-induced 
inflammation. Consequently, integrating the above results allows the conclusion that neither 
immature HSPCs nor mature hematopoietic cells (i.e. monocytes / macrophages or T 
lymphocytes) but instead non-hematopoietic BM cells are the most relevant source of IL-6, both 
systemically as well as locally in the BM, following LPS-induced inflammation.  
Results from our gene expression analyses (Figure 1C) strongly suggest that CAR cells 
represent this BM-resident non-hematopoietic cell type responsible for IL-6 production upon LPS 
stimulation. In order to provide more evidence for this conclusion, we employed Lepr-Cre mice 
which have been shown to relatively specifically target perivascular non-hematopoietic BM cell 
populations largely overlapping with CAR cells [73, 77]. Breeding Lepr-Cre mice with Il6fl/fl mice 
[130] generated mice with an Il6 deficiency in perivascular non-hematopoietic BM cells including 
CAR cells (Lepr-Cre;Il6fl/fl mice). Notably, LPS-induced elevation of IL-6 plasma and BM levels as 
measured by ELISA was almost completely abrogated in Lepr-Cre;Il6fl/fl mice, whereas control 
mice responded normally with an increase in IL-6 levels (Figure 2E). 
In summary, by combining several independent experimental in vitro and in vivo models our 
data strongly suggests that, BM CAR cells are indeed the major source of IL-6 in plasma and BM 
following LPS-induced inflammation.  
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Figure 2. IL-6 expression in total tissue extracts from various organs and IL-6 levels in PB 
and BM lysates of reciprocal Il6-/- BM chimeric mice as well as Lepr-Cre;Il6fl/fl and Rag1-/- 
mice following a single LPS injection. 
(A) Experimental outline illustrating induction of LPS-induced inflammation in WT, Il6-/- BM 
chimeric, Rag1-/-, and Lepr-Cre;Il6fl/fl mice prior to isolation of major solid organs and collection of 
plasma and BM lysates for RT-qPCR and ELISA, respectively. This schedule is applicable to 
experimental data depicted in panels B – E. (B) Il6 expression relative to Gapdh following LPS 
stimulation in whole tissue extracts from total bone, spleen, lung, kidney, heart, and liver of WT 
mice. (C-E) IL-6 protein levels in steady-state (PBS injected) plasma and BM lysates or after LPS 
stimulation in Il6-/- BM chimeric mice (C), Rag1-/- mice (D), and Lepr-Cre;Il6fl/fl mice (E); nd, not 
detectable; wd, weakly detectable. (ns, non-significant; *, p=0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001). 
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Supplemental Figure 2. Short-term kinetics of systemic and BM IL-6 levels following a 
single LPS injection. 
(A) and (B) Time course over 72 hours of systemic and local BM IL-6 levels following a single LPS 
injection (blue square) into WT mice as compared to PBS-injected (black squares) control mice. 
Data from three independent experiments are shown. 
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IL-6 is dispensable for emergency hematopoiesis during short-term LPS-induced 
inflammation 
Having revealed the primary source of IL-6 following LPS stimulation we set out to 
determine the functional impact of IL-6 on the course of LPS-induced emergency hematopoiesis. 
To this end, we used a well-established model of emergency hematopoiesis that we have 
previously shown to elicit a strong, primarily G-CSF-dependent hematopoietic response, i.e. de 
novo granulocyte production from upstream HSPCs [46, 56]. WT and Il6-/- mice were injected with 
two high-doses of LPS separated by a 48-hour interval, sacrificed 24 hours after the second LPS 
injection, and then analyzed for their HSPC and myeloid cell populations in BM by FACS (Figure 
S3A). As expected, there was a mostly significant change in the BM cellularity as well as absolute 
numbers of HSPCs and myeloid cell populations in BM of LPS-treated WT and Il6-/- mice as 
compared to PBS-treated WT and Il6-/- mice, respectively, indicating a physiological hematopoietic 
response towards LPS in both genotypes (Figure S3B and S3C). However, there were no 
statistically significant differences in the response pattern or magnitude between LPS-treated WT 
and Il6-/- mice. These results clearly demonstrate that IL-6 is dispensable for emergency 
hematopoiesis, at least during short-term LPS stimulation. 
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Supplemental Figure 3.  Hematopoietic response in BM of Il6-/- mice following short-term 
LPS treatment. 
(A) Graphical scheme depicting experimental outline for the induction of acute, short-term 
inflammation. (B) BM cellularity and absolute numbers per hind leg of immunophenotypically-
defined LT-HSCs, HPCs, GMPs, CD11b+Gr1high and CD11b+Gr1low cells in LPS (red bars) or PBS 
(white bars) treated WT and Il6-/- mice according to the treatment schedule depicted under Fig. 
S3A. Data from three independent experiments are shown. 
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IL-6 is required to adequately increase numbers of immunophenotypically defined HSPCs 
and to maintain myeloid cell numbers during chronic-repetitive LPS-induced inflammation  
 In light of the above negative results for a role of IL-6 in the regulation of acute emergency 
hematopoiesis during short-term LPS stimulation, we hypothesized that IL-6 may have a regulatory 
function only during prolonged inflammatory conditions. Therefore, we subjected WT and Il6-/- mice 
to an LPS treatment scheme consisting of a total of 9 high-dose LPS injections over a period of 3 
weeks followed by assessment of emergency hematopoiesis 24 hours after the last LPS injection 
(Figure 3A). BM HSPC and myeloid populations were defined by FACS (Figure 3B). Unlike short-
term LPS stimulation (Figure S3B and S3C), chronic-repetitive LPS treatment led to significant 
differences between the responses observed in WT and Il6-/- mice. While chronic-repetitive LPS 
stimulation of WT mice leads to only a slightly but still significantly reduced BM cellularity, this 
decrease in BM cellularity is significantly more pronounced in Il6-/- mice (Figure 3C). Furthermore, 
although the percentages of BM HSPC and myeloid populations were similar in LPS-treated WT 
and Il6-/- mice (Figure S4), there was a significant, approximately 50% reduction in the LPS-
induced increase in absolute cell numbers of Lin-Sca-1+c-kit+CD150+CD48- long-term HSCs and 
Lin-Sca-1+c-kit+CD150+/-CD48+ hematopoietic progenitors (HPCs) in Il6-/- mice compared to WT 
mice (Figure 3D). In addition, Lin-Sca-1-c-kit+CD34+FcgR+ granulocyte-macrophage progenitors 
(GMPs), CD11b+Gr1low and CD11b+Gr1high myeloid cells which are largely equivalent to 
promyelocytes / myelocytes and mature neutrophils, respectively [131, 132], failed to increase or 
even decreased during chronic-repetitive LPS stimulation in BM of Il6-/- mice compared to WT mice 
(Figure 3D). In order to formally prove that CAR cell-derived IL-6 is responsible for the above-
described failure in maintaining an appropriate quantitative hematopoietic response following 
chronic-repetitive LPS stimulation, we repeated the above experiment in Lepr-Cre;Il6fl/fl and control 
mice. As expected, we observed an identical response pattern after chronic-repetitive LPS 
treatment in Lepr-Cre;Il6fl/fl mice as compared to Il6-/- mice (Figure 3E and F). 
Moreover, IL-6 levels in plasma and BM lysates of WT ⇒ WT and Il6-/- ⇒ WT mice 
subjected to chronic-repetitive LPS stimulation increased significantly and indistinguishable from 
each other (Figure 3G), whereas Il6-/- ⇒ Il6-/- and WT ⇒ Il6-/- mice were non- or severely hypo-
responsive (Figure 3G). The same response pattern was also observed when Lepr-Cre;Il6fl/fl mice 
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underwent chronic-repetitive LPS stimulation (Figure 3H), indicating that even in the setting of 
prolonged LPS-induced inflammation systemic and local BM IL-6 levels depend on non-
hematopoietic CAR cells. Notably, the overall magnitude of IL-6 production was substantially 
reduced after chronic LPS stimulation (Figure 3G and H) as compared to a single high-dose LPS 
injection (Figure 2C and E). Longitudinal measurements of plasma and BM IL-6 levels in WT mice 
during chronic-repetitive LPS stimulation revealed that, in fact, after an initial extremely high peak 
in plasma and BM IL-6 abundance, IL-6 levels remain significantly elevated throughout the 3-week 
period, however, at much lower levels (Figure S5). These results strongly suggest that 
maintenance of elevated IL-6 levels requires constant de novo IL-6 production in non-
hematopoietic CAR cells whereas the initial IL-6 peak is presumably a consequence of a secretory 
burst from preformed IL-6 storage pools. 
Collectively, our data demonstrates that CAR cell-derived IL-6 is required to adequately 
increase numbers of immunophenotypically defined HSPC populations and to maintain myeloid 
cell numbers during emergency hematopoiesis elicited by chronic-repetitive LPS-induced 
inflammation. 
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Figure 3. Hematopoietic response in BM of Il6-/- and Lepr-Cre;Il6fl/fl mice upon chronic-
repetitive LPS treatment. 
(A) Graphical scheme depicting experimental outline for modeling chronic inflammation by 
repetitive LPS injections over a period of 3 weeks followed by analysis of different hematopoietic 
cell types as well as measurement of IL-6 levels in plasma and BM lysates. This schedule is 
applicable to experimental data depicted in panels C – H. (B) Representative FACS profile 
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showing gating strategy for the identification of hematopoietic stem and progenitor cells (LT-HSC 
and HPC), myeloerythroid progenitors (CMP, common myeloid progenitor; GMP, granulocyte-
macrophage progenitor; MEP, megakaryocyte-erythrocyte progenitor) as well as immature 
(CD11b+Gr1low) and mature granulocytic cells (CD11b+Gr1high) in PBS- and LPS-treated Il6-/-, Lepr-
Cre;Il6fl/fl, and respective control mice. (C) BM cellularity and (D) absolute numbers per hind leg of 
immunophenotypically-defined LT-HSCs, HPCs, GMPs, CD11b+Gr1high and CD11b+Gr1low cells in 
LPS (red bars) or PBS (white bars) treated WT and Il6-/- mice according to the treatment schedule 
depicted under Fig. 3A. (E) BM cellularity and (F) absolute numbers of immunophenotypically-
defined LT-HSCs, HPCs, GMPs, CD11b+Gr1high and CD11b+Gr1low cells in LPS (blue bars) or PBS 
(white bars) treated control and Lepr-Cre;Il6fl/fl mice according to the treatment schedule depicted 
under Fig. 3A. (G) IL-6 protein levels as measured by ELISA in plasma and BM lysates of Il6-/- BM 
reciprocal chimeric mice following PBS (white bars) or LPS (yellow bars) injection according to the 
experimental scheme shown in Fig. 3A. (H) IL-6 protein levels as measured by ELISA in plasma 
and BM lysates of Lepr-Cre;Il6fl/fl mice following PBS (white bars) or LPS (blue bars) injection 
according to the experimental scheme shown in Fig. 3A. (ns, non-significant; *, p=0.05; **, p<0.01; 
***, p<0.001; ****, p<0.0001). 
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Supplemental Figure 4. Hematopoietic response in BM of Il6-/- and Lepr-Cre;Il6fl/fl mice upon 
chronic-repetitive LPS treatment.  
(A) Graphical scheme depicting experimental outline for modeling chronic inflammation by 
repetitive LPS injections over a period of 3 weeks followed by analysis of different hematopoietic 
cell types by FACS. This schedule is applicable to experimental data depicted in panels B and C. 
(B) Percentages of immunophenotypically-defined LT-HSCs, HPCs, GMPs, CD11b+Gr1high and 
CD11b+Gr1low cells in the BM of LPS (red bars) or PBS (white bars) treated WT and Il6-/- mice 
according to the treatment schedule depicted under Fig. S4A. (C) Percentages of 
immunophenotypically-defined LT-HSCs, HPCs, GMPs, CD11b+Gr1high and CD11b+Gr1low cells in 
the BM of LPS (blue bars) or PBS (white bars) treated control and Lepr-Cre;Il6fl/fl mice according to 
the treatment schedule depicted under Fig. S4A. Data from three independent experiments are 
shown. 
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Supplemental Figure 5. Longitudinal analysis of systemic and BM IL-6 levels during 
chronic-repetitive LPS administration. 
(A) and (B) systemic and local BM IL-6 levels in WT mice during chronic-repetitive LPS stimulation 
(blue square) as compared to PBS-injected (black squares) control mice. Mice received the 
indicated number of LPS or PBS-injections (1, 2, 3, 5, 7, or 9 injections) over a maximum period of 
3 weeks and were sacrificed 4 hours after the last injection. Data from three independent 
experiments are shown. 
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IL-6 is required to increase the number of functional myeloid CFUs during chronic-repetitive 
LPS-induced inflammation in vivo and is able to directly stimulate enhanced myeloid CFU 
activity in vitro 
Having demonstrated that CAR cell-derived IL-6 plays a critical role in appropriately 
regulating quantities of immunophenotypically defined HSPC and myeloid cell populations during 
chronic-repetitive LPS-induced inflammation, we set out to also functionally evaluate these findings 
as there is only a weak correlation between HSPC immunophenotype and HSPC functionality, 
especially under inflammatory conditions known to alter expression of cell surface molecules 
commonly used to immunophenotypically define HSPC populations [133]. To this end, WT and Il6-/- 
mice received a chronic-repetitive high-dose LPS treatment of 9 injections during 3 weeks. Twenty-
four hours after the last LPS injection, mice were euthanized, whole BM cells were isolated and 
subjected to a fully cytokine-supplemented (incl. IL-6) colony-forming unit (CFU) assay which 
represents the gold-standard for detection of functional HSPCs in vitro (Figure 4A). Not 
surprisingly, there was a substantial and highly significant increase in total colony formation 
primarily due to increased numbers of granulocytic colonies (CFU-G) in LPS-treated WT mice as 
compared to PBS-injected WT mice (Figure 4B). In stark contrast to LPS-treated WT mice, 
chronic-repetitive LPS treatment of Il6-/- mice failed to increase colony formation and also led to a 
significant decrease of total CFUs, not only resulting from a decrease in CFU-G but rather a more 
general decline in CFU activity (Figure 4B). Of note, the fact that IL-6 was contained in the cytokine 
cocktail used in our CFU assay demonstrates that in vitro IL-6 supplementation does not suffice to 
rescue the hematopoietic phenotype in vitro resulting from in vivo IL-6 deficiency. Importantly, 
when we conducted the same experiment as described above in Lepr-Cre;Il6fl/fl and control mice, 
we observed an identical response (Figure 4C) corroborating that CAR cell-derived IL6 is indeed 
primarily responsible for increasing hematopoietic output from HSPCs during emergency 
hematopoiesis induced by chronic-repetitive LPS treatment. 
Next, we addressed the question as to whether CAR cell-derived IL-6 could act directly on 
HSPCs or via indirect mechanisms. First, we assessed cell surface expression of the ligand-
binding subunit of the Interleukin-6 receptor, i.e. IL-6Rα (CD126) on HSPC and myeloid cell 
populations by flow-cytometry. We could observe detectable CD126 expression on all HSPC cell 
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populations except for megakaryocyte-erythrocyte progenitors (MEPs), however at very different 
intensities (Figure 4D). Interestingly, with the exception of MEPs, CD126 expression as measured 
by mean fluorescence intensity (MFI) gradually increased within the HSPC populations with lowest 
CD126 expression found in Lin-Sca-1+c-kit+CD150+CD48- LT-HSCs and highest expression 
detected in Lin-Sca-1-c-kit+CD34+FcγR+ GMPs (Figure 4D). CD126 expression could also be 
robustly detected in more differentiated myeloid cells (CD11b+Gr1low and CD11bGr1high) albeit at 
lower levels than in GMPs. Strikingly, when we evaluated the expression of gp130 (CD130) which 
acts as the signal-transducing subunit of the IL-6R, we observed an inverse expression pattern 
with highest CD130 expression in LT-HSCs and lowest expression in GMPs (Figure 4E). These 
results demonstrate that HSPCs including immunophenotypically defined LT-HSCs by virtue of 
their CD126 / CD130 expression possess the necessary prerequisites to functionally respond to IL-
6 via IL-6R cis- and trans-signaling. Moreover, the observation that GMPs exhibit highest CD126 
expression may suggest that GMPs represent the major IL-6 responsive HSPC population by cis-
signaling whereas LT-HSCs may be particularly sensitive for IL-6 trans-signaling. 
In order to functionally test whether HSPCs could directly respond to IL-6 we performed 
serial re-plating CFU assays with c-kit-enriched HSPCs isolated from BM of steady-state WT mice 
cultured in vitro in the presence or absence of IL-6 but in otherwise fully cytokine-supplemented 
methylcellulose medium (Figure 4F). We observed that the number of possible serial re-platings 
was independent of the presence or absence of IL-6 as both HSPCs cultured in vitro with or 
without IL-6 were incapable of forming colonies beyond the first re-plating (Figure 4F). However, 
and of note, HSPCs cultured in the presence of IL-6 were able to generate significantly more 
colonies both during the initial culture period as well as following the first re-plating when equal 
numbers of cells harvested from the initial cultures were re-plated (Figure 4F). These data strongly 
suggest that IL-6 could directly act on HSPCs, and that IL-6 signaling prolongs in vitro 
hematopoietic progenitor (HPC) maintenance. 
Altogether, our results clearly demonstrate that CAR cell-derived IL-6, most likely via direct 
cis- or trans-signaling in HSPC populations, is critical to sustain emergency hematopoiesis during 
chronic-repetitive LPS-induced inflammation, as IL-6 deficiency in CAR cells leads to a failure to 
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adequately increase absolute numbers and functionality of HSPCs resulting in reduced BM 
cellularity, reduced BM myeloid CFUs, and decreased numbers of BM granulocytes.  
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Figure 4. CFUs in BM of Il6-/- and Lepr-Cre;Il6fl/fl mice upon chronic-repetitive LPS treatment 
and evidence for direct IL-6 action on HSPCs. 
(A) Experimental outline illustrating chronic-repetitive LPS treatment of Il6-/-, Lepr-Cre;Il6fl/fl and 
control mice followed by collection of whole BM cells which were subjected to colony-forming unit 
(CFU) assays. This schedule is applicable to experimental data depicted in panels B and C. (B) 
and (C) CFU activity shown as absolute CFU number per 1 hind leg in the BM of Il6-/-, Lepr-
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Cre;Il6fl/fl and respective control mice after chronic-repetitive in vivo LPS treatment according to 
Fig. 4A. (D) Left panel shows a representative flow-cytometric analysis for CD126 (IL-6R alpha 
chain, blue histograms) expression in LT-HSC, HPC, CMP, GMP, MEP, CD11b+Gr1high and 
CD11b+Gr1low cells in steady-state WT mice as compared to appropriate isotype controls (grey 
histograms). Right panel shows the delta mean fluorescent intensities (MFI) as calculation of MFI 
testor – MFI isotype control from 3 independent experiments. (E) Left panel shows a 
representative flow-cytometric analysis for CD130 (gp130, red histograms) expression in LT-HSC, 
HPC, CMP, GMP, MEP, CD11b+Gr1high and CD11b+Gr1low cells in steady-state WT mice as 
compared to appropriate isotype controls (grey histograms). Right panel shows the delta mean 
fluorescent intensities (MFI) calculated as described above. Results from 3 independent 
experiments are shown. (F) CFU activity in c-Kit-enriched BM cells isolated from steady-state WT 
mice and cultured in the presence or absence of IL-6 but in otherwise fully cytokine-supplemented 
methylcellulose medium (initial plating 0°). After 7 days in culture, colonies were scored, cells 
harvested, 3’000 cells were re-plated (1° re-plating) and grown under the same conditions (i.e. +/- 
IL-6) for another 7 days. Upon the second re-plating (2°) no colony growth could be observed. 
(CFU-G, CFU granulocyte; CFU-M, CFU macrophage; CFU-GM, CFU granulocyte/macrophage; 
CFU-GEMM, CFU granulocyte/ erythrocyte/ macrophage/ megakaryocyte; BFU-E, burst-forming 
unit erythrocyte). (ns, non-significant; *, p=0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001). 
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Systemic and local BM IL-6 levels during LPS-induced chronic-repetitive inflammation 
depend on Tlr4 expression by non-hematopoietic cells 
 Our above-described data reveals a regulatory pathway that translates inflammatory 
signals derived from LPS stimulation into secretion of IL-6 from BM-resident CAR cells, and IL-6, in 
turn, then acts on HSPCs to sustain emergency hematopoiesis during chronic-repetitive 
inflammation. However, it remained to be determined whether sensing of LPS occurs directly in 
CAR cells followed by IL-6 secretion or whether LPS sensing is accomplished in another cell type 
that, in turn, stimulates IL-6 secretion from CAR cells via an intermediate signal.  
To address this question, first, we determined expression of all relevant murine Toll-like 
receptors (Tlr1-9) in CAR cells by RT-qPCR. We also isolated, and then pooled conventional 
dendritic cells (cDCs) as well as plasmacytoid dendritic cells (pDCs) - thereafter referred to as DCs 
– to serve as a control for expression analyses since DCs are known to robustly express Tlr genes 
[32] (Figure 5A). We observed surprisingly high expression of a variety of Tlr genes in CARs at 
similar levels compared to DCs, in which TLR biology has been studied most extensively (Figure 
5B). Importantly, among the most highly expressed Tlr genes in CAR cells was Tlr4 – the cognate 
receptor for LPS thereby demonstrating that CAR cells are equipped with the molecular machinery 
to sense and respond to LPS. In order to test whether CAR cells are directly involved in LPS 
sensing in vivo, we faced the problem that available methodologies do not allow to specifically 
ablate Tlr4 in CAR cells in vivo. Therefore, we generated reciprocal BM chimeric mice with Tlr4 
expression compartmentalized to either hematopoietic (WT ⇒ Tlr4-/-) or non-hematopoietic cells 
(Tlr4-/- ⇒ WT) and respective control mice (WT ⇒ WT and Tlr4-/- ⇒ Tlr4-/-). We subjected these 
mice to either a single high-dose LPS injection or chronic-repetitive high-dose treatment and 
measured IL-6 levels in plasma and BM lysates by ELISA (Figure 5C). While LPS sensing by both 
hematopoietic and non-hematopoietic cells equally contributes to local BM IL-6 levels following a 
single high-dose LPS injection (Figure 5D right panel), systemic IL-6 levels largely depend on Tlr4 
expression by non-hematopoietic cells irrespective of the duration of LPS treatment (Figure 5D 
right panel and Figure 5F left panel). Strikingly however, upon chronic-repetitive LPS stimulation, 
local BM IL-6 levels are maintained exclusively by non-hematopoietic cells (Figure 5F right panel). 
Although we cannot definitively rule out a contribution of other non-hematopoietic cell types in 
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LPS-sensing leading to IL-6 secretion from CAR cells, our above-described data demonstrating 
strong Tlr4 expression in CAR cells in conjunction with our results from systemic and local BM IL-6 
levels in Tlr4-/- BM chimeric mice suggest that CAR cells may indeed directly sense LPS in vivo. 
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Figure 5. Toll-like receptor expression by non-hematopoietic stromal cell populations and 
IL-6 levels in reciprocal Tlr4-/- mice upon chronic-repetitive LPS treatment. 
(A) Experimental outline depicting isolation of CAR cells from BM as well as conventional dendritic 
cells (cDCs) and plasmacytoid dendritic cells (pDCs) from spleen of steady-state WT mice for the 
assessment of Tlr expression as shown in Fig. 5B. (B) Tlr1-9 expression as assessed by RT-qPCR 
in CAR cells (black bars) and DCs (pooled cDCs and pDCs, grey bars) isolated from steady-state 
WT mice. Expression values were normalized to housekeeping gene Gapdh. (C) Experimental 
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scheme showing induction of LPS-induced inflammation by a single LPS injection. This schedule is 
applicable to experimental data depicted in panel D. (D) IL-6 plasma and BM lysate levels in Tlr4-/- 
BM reciprocal chimeric mice upon a LPS-induced inflammation (yellow bars) in comparison to 
PBS-injected control mice (white bars). (E) Graphical scheme depicting experimental outline for 
chronic-repetitive LPS-induced inflammation. This schedule is applicable to experimental data 
depicted in panel F. (F) IL-6 plasma and BM lysate levels in Tlr4-/- BM reciprocal chimeric mice 
upon a LPS-induced inflammation (orange bars) in comparison to PBS-injected control mice (white 
bars). (ns, non-significant; *, p=0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001). 
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Discussion 
In this study, we intended to get a deeper insight into how the non-hematopoietic BM 
microenvironment, that is known to be essential for proper functionality of steady-state 
hematopoiesis, may also be involved in regulating inflammation-driven emergency hematopoiesis. 
We hypothesized that, first, non-hematopoietic BM cells would be responsive towards infectious / 
inflammatory signals, and that second, inflammation-induced changes in non-hematopoietic BM 
cells would also reflect essential growth factor requirements of HSPCs during inflammation-driven 
emergency hematopoiesis. Therefore, we performed expression analyses for a selection of twelve 
prototypic hematopoietic growth factors and cytokines on different prospectively isolated non-
hematopoietic cells from mice that were stimulated in vivo with LPS or poly(I:C) to mimic bacterial 
or viral infection, respectively. We identified Il6 to be significantly, highly and relatively specifically 
up-regulated in CAR cells upon LPS but not poly(I:C) stimulation. Additional extensive 
experimentation comprising Il6 expression analyses in whole tissue extracts from major solid 
organs and total bone, reciprocal Il6-/- BM chimeric mice, and conditional ablation of Il6 in CAR 
cells using Lepr-Cre;Il6fl/fl mice yielded results that clearly demonstrated that CAR cells are the 
primary source of IL-6 during LPS-induced inflammation. These results seem surprising given the 
prevailing notion that inflammatory cytokines are mostly secreted from bona fide immune cells 
such as monocytes, macrophages and T cells. However, it has been known for a long time that 
both hematopoietic as well as non-hematopoietic cell types are capable of constitutive and 
inducible production of hematopoietic cytokines but these data are mostly derived from in vitro 
studies of cell lines or in vitro cultured primary cells [134-137]. Importantly, the in vivo contribution 
of various cell types to cytokine abundance under specific inflammatory settings is largely unknown 
and the here presented data demonstrates the need for proper in vivo experimentation when 
studying biological consequences of temporospatial and contex-dependent cytokine availabilities.  
Another caveat might be the assumed low frequency of non-hematopoietic BM cells 
including CAR cells in mouse BM [68, 138, 139] and that such a scarce cell population could 
hardly account for systemically measurable IL-6 levels. However, it needs to be noted that FACS-
based quantification of non-hematopoietic BM cell numbers [120] is massively underestimating the 
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actual frequency of these cells in mouse BM when compared to more sophisticated imaging 
technologies [65, 77] indicating that cell isolation procedures performed prior to flow-cytometrical 
analyses lead to suboptimal cell recovery. Consequently, CAR cells are a much more abundant 
cell population than previously thought underscoring their importance as a major source of IL-6 
during LPS-induced inflammation. 
 In longitudinal analyses we also observed remarkable differences between initial systemic 
and local BM IL-6 levels as compared to those measured after repeated LPS stimulation. A 
putative explanation for this observation is a phenomenon called endotoxin tolerance (ET) 
occurring during chronic gram-negative bacterial infection. ET is believed to be a protective 
mechanism to prevent excessive hyper-inflammation. During ET, monocytes and macrophages 
enter an unresponsive state as a consequence of repeated exposure to endotoxins (e.g. LPS) and 
hence show an inability to respond to further LPS challenges [140, 141]. Whether ET also occurs 
in CAR cells following chronic-repetitive LPS stimulation remains to be determined. Importantly, 
despite an initial high burst in IL-6 levels followed by a rapid decrease in maximum IL-6 levels 
during subsequent chronic-repetitive LPS stimulation, IL-6 remains continuously and significantly 
elevated, and local BM concentrations may even be higher where HSPCs respond towards CAR 
cell-derived IL-6. 
Testing the functional hematopoietic consequences of IL-6 during short-term LPS-induced 
inflammation revealed that IL-6 deficiency does not cause a measurable deficit in the elicited 
emergency hematopoiesis response. This observation is in line with published data demonstrating 
that emergency granulopoiesis is mainly driven by G-CSF at least during the initial phase [4, 5, 56]. 
In stark contrast, when we prolonged LPS stimulation thereby mimicking chronic-repetitive 
inflammation / infection, Il6-/- and Lepr-Cre;Il6fl/fl mice developed BM hypocellularity compared to IL-
6-competent mice. Furthermore, FACS analyses demonstrated a moderate but highly significant 
impairment in the ability to increase absolute numbers of immunophenotypically-defined LT-HSCs 
and HPCs in Il6-/- and Lepr-Cre;Il6fl/fl mice upon chronic-repetitive LPS stimulation. Moreover, IL-6 
deficiency led to a severe quantitative deficit in myeloid specific progenitors (GMPs) and 
downstream granulocytic cells (CD11b+Gr1low/high). Importantly, these quantitative phenotypes also 
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resulted in a severe functional defect in generating CFUs in the BM of LPS-treated Il6-/- and Lepr-
Cre;Il6fl/fl mice.  
How do these results compare to published hematopoietic functions of IL-6? Although it has 
been known for over 20 years that IL-6 promotes hematopoiesis [112],two recent papers have 
reported on the role of IL-6 during inflammation-induced emergency hematopoiesis using state-of-
the-art methodologies [39, 57].  
Using single-cell proteomics Zhao et al. found that HSPCs are able to sense TLR agonists in vitro 
leading to the secretion of inflammatory cytokines including IL-6 which, in turn, could act in an 
autocrine / paracrine manner to stimulate enhanced HSPC proliferation and myeloid differentiation. 
While this interesting finding is likely to be biologically meaningful, it was challenging to rigorously 
test its functionally importance. Zhao et al. therefore devised an elegant experiment demonstrating 
that, under very specific experimental conditions of BM transplantation in a severely leukopenic 
host devoid of endogenous HSPCs, transplanted donor WT HSPCs were more efficient to 
generate myeloid offspring as opposed to Il6-/- donor HSPCs. Of note, our results presented here 
unambiguously demonstrated that hematopoietic cell-derived IL-6 is dispensable for emergency 
hematopoiesis during chronic-repetitive LPS stimulation but clearly showed that CAR cells are the 
major source of IL-6. This obvious discrepancy can be reconciled by the different experimental 
approaches reflecting fundamentally different clinical settings. The findings by Zhao et al. suggest 
that HSPC-derived IL-6 may be functionally relevant during the initial phase of hematopoietic 
recovery following myeloablative hematopoietic stem cell transplantation when the BM 
microenvironment is dysfunctional as a consequence of the conditioning regimen, and HSPCs may 
be able to compensate for growth factor deficiencies by the described autocrine / paracrine loop. 
However, our results obtained from a naturally-occurring setting of chronic infection / inflammation 
unequivocally demonstrates that the relative contribution of hematopoietic cells incl. HSPCs to IL-6 
levels is negligible but depends primarily on non-hematopoietic CAR cells.  
Furthermore, Schuerch et al. have recently reported a very interesting finding that, during viral 
infection, cytotoxic T cell-derived IFN stimulates IL-6 release from MSCs which, in turn, promotes 
monopoiesis. Of note, MSCs are distinct to CAR cells and thus, the findings by Schuerch et al. 
obtained from studies of acute viral infection as opposed to the here studied model setting of 
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chronic-repetitive bacterial infection do not contradict our data. On the contrary, our results in 
conjunction with findings by Schuerch et al. clearly demonstrate the versatility, flexibility and most 
importantly, context-dependency of growth factor provision by the BM microenvironment and 
should stimulate further research in this area. 
We also addressed the question as to whether CAR cell-derived IL-6 acts directly or 
indirectly on HSPCs thereby sustaining emergency hematopoiesis during chronic-repetitive 
inflammation. To this end, we assessed expression of both CD126 (i.e. IL-6Rα) representing the 
ligand-binding subunit of the IL-6R as well as CD130 (i.e. gp130) representing the signal-
transducing subunit. We observed detectable CD126 and CD130 expression at varying levels in 
HSPC and more differentiated myeloid cell populations with the exception of MEPs. Notably, we 
found an inverse pattern of differential expression between CD126 and CD130. While LT-HSCs 
express relatively low levels of CD126 but high levels of CD130, the opposite pattern was 
observed in GMPs. It needs to be noted that IL-6 signaling can either occur via membrane-bound 
IL-6R (cis-signaling) or through soluble IL-6Rα (trans-signaling). The latter dimerizes with 
membrane-bound gp130 triggering downstream signaling in a cell that does not endogenously 
express CD126 thereby increasing the target range of putative IL-6 responsive cell types.  It is 
tempting to speculate that the differential expression of CD126 and CD130 in LT-HSCs versus 
GMPs has a functional relevance but further studies are required to test this hypothesis. 
Finally, we set out to address the question as to whether CAR cells are directly sensing 
LPS followed by IL-6 secretion or whether LPS-sensing is accomplished in another cell type that, 
in turn, delivers an intermediate signal to CAR cells leading to IL-6 secretion. Due to current 
technical limitations, our data cannot provide a definitive answer to this question as this would 
require the ability to specifically delete Tlr4 in CAR cells. However, our data strongly suggests that 
CAR cells are indeed directly sensing LPS as indicated by their high expression of Tlr4, the 
cognate receptor for LPS, and, based on to the observation that – especially during chronic-
repetitive LPS-stimulation – systemic and local BM IL-6 levels depend on Tlr4 expression by non-
hematopoietic cells as determined in reciprocal BM Tlr4-/- chimeric mice. 
 In summary, using gene expression analyses in prospectively isolated non-hematopoietic 
BM cell populations in combination with several mouse models we here show that CAR cells are 
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the primary source of systemic and local BM IL-6 following LPS stimulation. Most importantly, while 
IL-6 is dispensable during the initial phase of LPS-induced emergency hematopoiesis, it is 
essential to sustain emergency hematopoiesis during chronic-repetitive inflammation. Our findings 
highlight the previously underappreciated and emerging role of the BM microenvironment as active 
participant in innate immune responses and critical regulator of demand-adapted hematopoiesis 
during infection and inflammation.  
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Results III 
 
This is an article about the involvement of endothelial cells in the translation of pathogen signals 
into emergency granulopoiesis. I contributed to this article by assisting in the conduction of 
experiments such as flow cytometry cell sorting, qPCR and Elisa analysis.  
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Endothelial cells translate pathogen signals into G-CSF–driven
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Steffen Boettcher,1 Rahel C. Gerosa,1 Ramin Radpour,1 Judith Bauer,2 Franziska Ampenberger,3 Mathias Heikenwalder,2
Manfred Kopf,3 and Markus G. Manz1
1Division of Hematology, University Hospital Zurich, Zurich, Switzerland; 2Institute for Virology, Technical University Munich/Helmholtz Center Munich,
Munich, Germany; and 3Institute for Molecular Health Sciences, Molecular Biomedicine, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland
Key Points
• ECs express Tlr4 and Myd88
and, after in vivo LPS or E coli
stimulation, are the prime
sources of G-CSF.
• ECs are sensors of
systemically spread pathogens
and subsequent drivers of BM
emergency granulopoiesis.
Systemic bacterial infection induces a hematopoietic response program termed “emer-
gency granulopoiesis” that is characterized by increased de novo bone marrow (BM)
neutrophil production. How loss of local immune control and bacterial dissemination
is sensed and subsequently translated into the switch from steady-state to emergency
granulopoiesis is, however, unknown. Using tissue-specific myeloid differentiation
primary response gene 88 (Myd88)-deficient mice and in vivo lipopolysaccharide (LPS)
administration to model severe bacterial infection, we here show that endothelial cells
(ECs) but not hematopoietic cells, hepatocytes, pericytes, or BM stromal cells, are essen-
tial cells for this process. Indeed, ECs from multiple tissues including BM express high
levels of Tlr4 andMyd88 and are the primary source of granulocyte colony-stimulating
factor (G-CSF), the key granulopoietic cytokine, after LPS challenge or infection with
Escherichia coli. EC-intrinsicMYD88 signaling and subsequentG-CSFproductionbyECs
is required for myeloid progenitor lineage skewing toward granulocyte-macrophage progenitors, increased colony-forming unit
granulocyte activity in BM, and accelerated BMneutrophil generation after LPS stimulation. Thus, ECs catalyze the detection of systemic
infection into demand-adapted granulopoiesis. (Blood. 2014;124(9):1393-1403)
Introduction
Granulocytes are generated from upstream bone marrow (BM)
precursors under the control of various myeloid cytokines, most
importantly granulocyte colony-stimulating factor (G-CSF).1 Among
granulocytes, neutrophils are the dominant cell type in BM, peripheral
blood (PB), and tissues in the steady state and during bacterial
infection. Neutrophils serve as key ﬁrst line of defense cells of the
innate immune system.2 To exert their critical function, neutrophils
are recruited to respective sites of infection.2 Although some neu-
trophils are able to reenter the vasculature,3-5 the majority of cells
are consumed and undergo cell death in the inﬂamed tissue as a
consequence of launching their antimicrobial defense mechanisms.2
In locally poorly controlled and consequently systemically spread
microbial infection, neutrophils are in high demand and need to be
regenerated in large numbers. Hence, because of their already short
half-life in the steady state, ranging from a few hours to a few days,6
during severe systemic infection, steady-state granulopoiesis is switched
to “emergency granulopoiesis” (ie, massively enhanced de novo
neutrophil production in BM).7,8 Thus, besides efﬁcient neutrophil
recruitment to sites of infection and microbicidal neutrophil effector
functions,2 the third critical component of a protective innate im-
mune response is the ability of the hematopoietic system to launch
the emergency granulopoiesis program.
A prerequisite for the initiation of emergency granulopoiesis
is sensing of pathogen dissemination. Pattern-recognition receptors
such as Toll-like receptors (TLRs) recognize respective conserved
pathogen-associated molecular patterns as diverse as proteins,
polysaccharides, and nucleic acids.9 TLRs can be found on the cell
surface as well as within endosomal compartments, and TLR signal
transduction occurs via adaptor molecules such as MYD88 and
TRIF, leading to transcription of genes involved in the host response
toward invading pathogens.10 TLR expression and function has been
best characterized in mature immune effector cells.9 In addition,
accumulating evidence has revealed that nonhematopoietic cells
such as bladder epithelial cells,11 mesenchymal stromal cells,12,13
and endothelial cells (ECs)14,15 also express TLRs, thereby critically
contributing to innate immune responses. Furthermore, it has been
demonstrated that hematopoietic stem and progenitor cells (HSPCs)
express some TLRs and directly respond to pathogen-associated
molecular patterns with increased myelopoiesis and directed migra-
tion to inﬂamed sites.16-22 However, we have recently shown that
direct pathogen sensing by HSPCs does not play an essential role in
the immediate lipopolysaccharide (LPS)-induced emergency gran-
ulopoiesis response. By contrast, TLR4 agonist sensing by non-
hematopoietic cells followed by granulopoietic growth factor release,
primarily G-CSF, is the main route for the initiation of emergency
granulopoiesis.23
We address here the fundamental question of which cell type out
of the vast plethora of putative nonhematopoietic cells and tissues is
Submitted April 17, 2014; accepted June 22, 2014. Prepublished online as
Blood First Edition paper, July 2, 2014; DOI 10.1182/blood-2014-04-570762.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2014 by The American Society of Hematology
BLOOD, 28 AUGUST 2014 x VOLUME 124, NUMBER 9 1393
79 
 
 
 
the key sensor of systemically spread pathogens, speciﬁcally LPS
and Escherichia coli, and how this sensing is translated into
emergency granulopoiesis.
Methods
Mice
C57BL/6J (CD45.21), B6.SJL-Ptprca Pepcb/BoyJ (CD45.11), Myd882/2,
Tlr42/2, Trif2/2, LysM-Cre, Nes-Cre, Pdgfrb-Cre, Alb-Cre, Tie2-Cre,
Myd88ﬂl/ﬂ (B6.129P2(SJL)-Myd88tm1Defr/J), and loxP-GFP (B6.Cg-Gt(ROSA)
26Sortm6(CAGZsGreen1)Hze/J) mice were used in this study. All animals were
maintained at the University Hospital Zurich animal facility and treated in
accordancewith guidelines of the Swiss Federal VeterinaryOfﬁce. Experiments
and procedures were approved by the Veterina¨ramt des Kantons, Zurich,
Switzerland.
LPS injections, E coli infection, and G-CSF injections
Mice received 2 intraperitoneal injections with 35 mg ultrapure LPS from
E coli 0111:B4 (InvivoGen) 48 hours apart and were analyzed 24 hours after
the second injection. For some experiments, mice were administered 20 mg
LPS 3 times (at 0, 12, and 20 hours) andwere analyzed at time point 24 hours.
Alternatively, mice were intraperitoneally (IP)-injected with 0.5 to 4.53 108
E coli and analyzed 48 hours later. Somemicewere IP-injected with 250mg/kg
body weight human G-CSF (Filgrastim; Amgen) 6 times in a 12-hour interval
and analyzed as LPS-injected mice.
Flow cytometry
The following antibodies (all from eBiosciences, unless otherwise stated)
were used to assess mature BM and PB cell populations: anti-CD11b
(M1/70), anti-Gr1 (RB6-8C5), anti-Ly6-G (1A8; Biolegend), anti-Ly6-C
(HK1.4), anti-B220 (RA3-6B2), and anti-CD3e (145-2C11). For ﬂuorescence-
activated cell sorter (FACS) analysis of HSPCs, the following antibodies were
used: anti-CD3e (145-2C11), anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-B220
(RA3-6B2), anti-CD19 (MB19-1), anti-CD11b (M1/70), anti-Gr1 (RB6-8C5),
anti-Ter119 (Ter-119), anti-IL7Ra (A7R34), anti-cKit (2B8), anti-Sca1
(D7), anti-CD34 (RAM34), anti-FcgR (93), and anti-NK1.1 (PK136; Becton
Dickinson).
ECs were stained with anti-CD45 (30-F11), anti-TER119 (Ter-119), and
anti-CD31 (390). In some experiments, anti-VE-cadherin (BV13), anti-Sca1
(E13-161.7; BDBiosciences), anti-VCAM1 (429), and anti-CD105 (MJ7/18)
antibodies were used.
Classical and plasmacytoid dendritic cells were stained using anti-CD3e
(145-2C11), anti-CD19 (MB19-1), anti-NK1.1 (PK136; Becton Dickinson),
anti-CD45RA (14.8; BD Biosciences), anti-CD11c (N418), and anti-MHCII
(M5/114.15.2).
Hoechst33342 (LifeTechnologies)was used to exclude dead cells.Cellswere
analyzed or sorted on a FACS Canto II or FACS Aria III ﬂow cytometer (BD
Biosciences), respectively. Data were analyzed by FlowJo (Tree Star) software.
BrdU incorporation assay
Mice were injected with phosphate-buffered saline (PBS) or LPS according
to the scheme depicted in Figure 5A. Twelve hours before analysis, mice
received 1 single IP injection of 2 mg 5-bromo-29-deoxyuridine (BrdU;
Sigma-Aldrich). In addition, BrdU at a ﬁnal concentration of 0.8 mg/mL as
well as 5% glucose were added to the drinking water. Cells were isolated and
further processed according to the manufacturer’s protocol (BrdU Flow Kit;
BD Pharmingen).
Colony-forming unit (CFU) assay
After in vivo PBS or LPS stimulation according to the scheme depicted in
Figure 1A, 1 3 104 red blood cell–depleted whole BM cells were plated in
methylcellulose (Methocult M3234; StemCell Technologies) mixed with
Iscove’s modiﬁed Dulbecco’s medium (30% fetal calf serum, 2 mM
L-glutamine, 50mM2-mercaptoethanol) with the following factors added: mIL3
(10ng/mL), hIL6 (10 ng/mL), hIL11 (10 ng/mL),mFLT3-Ligand (10 ng/mL),
mSCF (10 ng/mL), mGM-CSF (10 ng/mL), huTPO (50 ng/mL), and huEPO
(4 U/mL) (all R&D Systems). Colonies were scored after 8 days of in vitro
culture.
Quantitative reverse-transcription PCR
ECs were sorted directly into lysis buffer belonging to RNeasy Micro Kit
(QIAGEN). Total RNA extraction was carried out according to the man-
ufacturer’s protocol and subsequently subjected to reverse transcription using
a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Quantitative real-time polymerase chain reaction (PCR) was performed using
SYBR green reagent (Applied Biosystems) and samples were run on a 7500
FAST real-time PCR thermal cycler (Applied Biosystems). Actb was used to
normalize the RNA content of samples.
Enzyme-linked immunosorbent assay
PB was obtained from mice postmortem by cardiac puncture using hep-
arinized syringes and centrifuged to obtain plasma.G-CSFplasma levelswere
measured using Quantikine ELISA kits according to the manufacturer’s
instructions (R&D Systems).
Equations and statistical analyses
Signiﬁcance of differences was analyzed using Student t test. A difference
between experimental groups was considered signiﬁcant when the P value
was ,.05. All statistical analyses were calculated with Prism software
(GraphPad Software, version 5.01).
Results
LPS-induced emergency granulopoiesis requires intact
MYD88-mediated TLR signaling in nonhematopoietic cells
To examine whether MYD88 expression within hematopoietic or
nonhematopoietic cells is required for LPS-induced emergency gran-
ulopoiesis, we generated BM chimeric mice with MYD88 expression
restricted to either the hematopoietic (wild-type [WT]→Myd882/2) or
the nonhematopoietic cellular compartment (Myd882/2→WT) as
well as respective control mice (WT→WT andMyd882/2→Myd882/2)
(Figure 1A). We IP-injected chimeric mice with high doses of LPS to
mimic severe systemic infection (Figure 1A) and analyzed typical
surrogate hallmarks of emergency granulopoiesis. Although absolute
leukocyte counts did not change signiﬁcantly in PB upon LPS stim-
ulation (data not shown), the frequency and absolute numbers of PB
CD11b1cells signiﬁcantly increased inWT→WTmice (Figure1B).This
response was completely absent in Myd882/2→Myd882/2 mice,
indicating that LPS-induced elevation in PB CD11b1 cells depends on
MYD88 signaling. Strikingly, althoughWT→Myd882/2mice were also
completely nonresponsive toward LPS, Myd882/2→WT mice showed
a normal LPS response (Figure 1B). Next, we analyzed the BM of
chimeric mice after LPS treatment.We found that total BM cell numbers
are signiﬁcantly decreased upon LPS stimulation in WT→WT mice
(Figure 1C). The reduction of BM cellularity is mediated in a MYD88-
dependent manner because Myd882/2→Myd882/2 mice did not show
this response. This depends on MYD88 expression within non-
hematopoietic cells because Myd882/2→WT mice responded nor-
mally but WT→Myd882/2 mice lacked this response (Figure 1C). A
characteristic feature of emergency granulopoiesis is a signiﬁcant,
relative, and absolute decrease in BM CD11b1Gr1high mature
neutrophils (Figure 1D-E). This response is paralleled by a signiﬁcant
relative increase inBMCD11b1Gr1low immature neutrophils23-25 and
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a trend toward an absolute increase in BM CD11b1Gr1low immature
neutrophils. These reciprocal changes in BMCD11b1Gr1high mature
neutrophils and BM CD11b1Gr1low immature neutrophils after LPS
injection require intact MYD88 signaling in nonhematopoietic cells
(Figure 1D-F).
Although various cytokines such as granulocyte-monocyte colony-
stimulating factor (GM-CSF), macrophage colony-stimulating factor,
interleukin-6, and G-CSF have the capacity to stimulate both steady-
state as well as emergency granulopoiesis, none of these cytokines
is absolutely essential.1,26-29 However, G-CSF plays an out-
standing role in these processes as demonstrated in studies of
G-csf2/2 and G-csfr2/2 mice showing hematopoietic defects in
steady state, andmost importantly, upon infection.1,30,31 Notably,
administration of recombinant G-CSF is routinely used to treat
iatrogenic32 and congenital33 neutropenia. Furthermore, G-CSF
alone is sufﬁcient to induce a response indistinguishable from
LPS-induced emergency granulopoiesis.23,34 We therefore as-
sessed G-CSF plasma levels in BM chimeric mice after LPS
stimulation. We found highly signiﬁcant increases in plasma
G-CSF levels in WT→WT and Myd882/2→WT mice (Figure 1G).
By contrast, Myd882/2→Myd882/2 and WT→Myd882/2 mice
did not show elevated plasma G-CSF levels. Thus, LPS-triggered
G-CSF release requires intact Myd88 within nonhematopoietic
cells.
To corroborate our ﬁndings on the importance of nonhemato-
poietic cells for the initiation of emergency granulopoiesis and to
further rule out a role for tissue-resident macrophages for this
process, we generated LysM-Cre;Myd88ﬂ/ﬂ mice with a Myd88
deﬁciency restricted to myeloid cells including macrophages.35 In line
with the results on hematopoietic chimeric animals, we observed that
Figure 1. LPS-induced emergency
granulopoiesis requires intact MYD88-
mediated TLR signaling in nonhema-
topoietic cells. (A) Graphical scheme
depicting experimental outline to induce
LPS-induced emergency granulopoiesis
in mice with MYD88 expression restricted
to hematopoietic (WT→Myd882 /2) or
nonhematopoietic (Myd882/2→WT) cells,
and respective control mice (WT→WT
and Myd882/2→Myd882/2). (B) Frequency
and absolute number of PB CD11b1 cells,
and (C) BM cellularity after LPS stimu-
lation in BM chimeric and control
mice. (D) Representative FACS profile
showing characteristic changes in BM
CD11b1Gr1high mature and BM CD11b1
Gr1low immature neutrophils after LPS
stimulation. (E) Frequencies and absolute
numbers of BM CD11b1Gr1high mature,
(F) BM CD11b1Gr1low immature neutro-
phils, and (G) plasma G-CSF levels in
reciprocal Myd882/2 BM chimeras upon
systemic LPS injection. Black squares,
PBS-injected mice; red squares, LPS-
injected mice; rel., relative; abs., absolute.
Data from 2 independent experiments are
shown. Two-tailed Student t tests were
used to assess statistical significance
(*P , .05, **P , .01, ***P , .001; ns,
nonsignificant).
BLOOD, 28 AUGUST 2014 x VOLUME 124, NUMBER 9 ENDOTHELIUM GUIDES EMERGENCY GRANULOPOIESIS 1395
81 
 
 
 
LysM-Cre;Myd88ﬂ/ﬂ mice are fully capable to launch emergency
granulopoiesis (supplemental Figure 1, available on the BloodWeb site).
Altogether, our results on MYD88 and previous data on TLR423
unambiguously show that LPS-induced emergency granulopoiesis
is initiated through TLR agonist sensing and MYD88-dependent
signaling by nonhematopoietic cells.
LPS-induced emergency granulopoiesis is abrogated in
Tie2-Cre;Myd88fl/fl mice
To unravel the identity of the nonhematopoietic cell type critical for
emergency granulopoiesis, we used Cre-loxP recombination technol-
ogy to delete Myd88 from various candidate nonhematopoietic cell
Figure 2. LPS-induced emergency granulopoiesis is abrogated in Tie2-Cre;Myd88fl/fl mice. (A) Frequency and absolute number of PB CD11b1 cells after LPS stimulation in
control Myd88fl/fl, and experimental Nes-Cre;Myd88fl/fl, Pdgfrb-Cre;Myd88fl/fl, Alb-Cre;Myd88fl/fl, and Tie2-Cre;Myd88fl/fl mice. (B) BM cellularity after LPS stimulation in control Myd88fl/fl,
and experimental Nes-Cre;Myd88fl/fl, Pdgfrb-Cre;Myd88fl/fl, Alb-Cre;Myd88fl/fl, and Tie2-Cre;Myd88fl/fl mice. (C) Representative FACS profile showing characteristic LPS-induced
changes in BMCD11b1Gr1high mature and BMCD11b1Gr1low immature neutrophils in controlMyd88fl/fl, and experimentalNes-Cre;Myd88fl/fl, Pdgfrb-Cre;Myd88fl/fl, Alb-Cre;Myd88fl/fl,
0and Tie2-Cre;Myd88fl/fl mice. (D) Frequencies and absolute numbers of BM CD11b1Gr1high mature and (E) BM CD11b1Gr1low immature neutrophils, and (F) plasma
G-CSF levels in the different sets of tissue-specific Myd882/2 mice after systemic LPS injection. Black squares, PBS-injected mice; red squares, LPS-injected mice; rel.,
relative; abs., absolute. Data from at least 3 independent experiments are shown. Two-tailed Student t tests were used to assess statistical significance (*P , .05, **P , .01,
***P , .001).
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populations to study their relative contribution to pathogen sensing
(supplemental Table 1). To achieveMyd88 deletion in cells of the BM
microenvironment (Nestin1 mesenchymal stem cells and perivascular
stromal cells), we used Nes-Cre36-38 and Pdgfrb-Cre39 mice. Cells
belonging to the vasculature (ECs and pericytes) were targeted using
Tie2-Cre40 and Pdgfrb-Cre39 mice, respectively. We also employed
Alb-Cre41 mice to target hepatocytes as a candidate parenchymal organ
cell type. First,we assessed theLPS response inPBof control and tissue-
speciﬁcMyd882/2mice. We observed that the frequency and absolute
numbers of PB CD11b1 cells signiﬁcantly increased in LPS-injected
Myd88ﬂ/ﬂ control, Nes-Cre;Myd88ﬂ/ﬂ, Pdgfrb-Cre;Myd88ﬂ/ﬂ, and
Alb-Cre;Myd88ﬂ/ﬂ mice, whereas Tie2-Cre;Myd88ﬂ/ﬂ mice lacked
the response (Figure 2A). The majority of PB CD11b1 cells could be
identiﬁed as neutrophils based on coexpression of Ly6-G, whereas PB
CD11b1Ly6-Chigh inﬂammatory monocytes showed a relative de-
crease but overall stable absolute numbers (supplemental Figure 2).
Next,we investigated theBMresponse towardLPS.Not only didwe
observe a decrease in BM cellularity in LPS-injectedMyd88ﬂ/ﬂ control,
Nes-Cre;Myd88ﬂ/ﬂ,Pdgfrb-Cre;Myd88ﬂ/ﬂ, andAlb-Cre;Myd88ﬂ/ﬂmice
(Figure 2B), we also revealed a reduction in the frequency and absolute
number of BM CD11b1Gr1high mature neutrophils (Figure 2C-D).
Although the percentage of BM CD11b1Gr1low immature neutrophils
was highly signiﬁcantly increased, there was only a minor increase in
absolute numbers that, likely because of the higher variation in BM
cellularity, did not always yield statistical signiﬁcance (Figure 2C,E).
Strikingly, Tie2-Cre;Myd88ﬂ/ﬂ mice were nonresponsive toward sys-
temic LPS injection, with the exception of a small but signiﬁcant
decrease inBMcellularity that was, however, signiﬁcantly reduced in
magnitude comparedwith the other groups ofmice (Figure 2B-E). In
line with these ﬁndings, G-CSF levels increased massively, up to
100-fold, in control and respective tissue-speciﬁc Myd882/2 mice
with the exception of Tie2-Cre;Myd88ﬂ/ﬂ mice that lacked a signiﬁ-
cant rise in plasma G-CSF concentration (Figure 2F).
ECs express high levels of Myd88 and Tlr4 and respond to LPS
challenge with strong upregulation of VCAM-1 and G-csf in vivo
Our ﬁndings suggested that ECs, which are targeted in Tie2-Cremice,
are the cells within the nonhematopoietic compartment responsible
Figure 3. Endothelial cells from various organs
express high levels of Myd88 and Tlr4, respond to
LPS challenge with strong upregulation of VCAM-1
and G-csf in vivo, and exogenous G-CSF admin-
istration rescues emergency granulopoiesis in
Tie2-Cre;Myd88fl/fl mice. (A) Myd88 and (B) Tlr4
expression were assessed by quantitative reverse-
transcription PCR in CD452Ter1192CD311ECs iso-
lated from BM, heart, liver, kidney, spleen, and lung (gray
bars) compared with spleen DCs (black bars), ie, pooled
classical dendritic cells (CD3e2CD192NK1.12CD11chigh
CD45RA2MHCII1) and plasmacytoid dendritic cells
(CD3e2CD192NK1.12CD11c1CD45RA1MHCIIhigh). All
cells were isolated from steady-state mice. (C) Graph-
ical scheme depicting experimental outline to assess
in vivo LPS responsiveness of ECs that were flow-
cytometrically sorted from BM, heart, liver, kidney,
spleen, and lung of PBS- and LPS-injected mice,
respectively. (D) Comparative G-csf transcript levels
normalized to Actb in ECs from BM, heart, liver, kidney,
spleen, and lung of LPS-injected (red bars) vs PBS-
injected (black bars) wild-type mice. (E) Representa-
tive FACS analysis depicting cell-surface expression of
VCAM1 (red lines) on BM ECs in steady state as well as
LPS-injected control Myd88fl/fl and Tie2-Cre;Myd88fl/fl
mice. Isotype control shown as blue line. (F) Graphical
scheme showing experimental outline to assess G-CSF
effects in vivo. (G) Representative FACS profile show-
ing characteristic G-CSF–induced changes in BM
CD11b1Gr1high mature and BM CD11b1Gr1low immature
neutrophils in control Myd88fl/fl and Tie2-Cre;Myd88fl/fl
mice. (H) Frequencies of BM CD11b1Gr1high mature and
(I) BM CD11b1Gr1low immature neutrophils in PBS- and
G-CSF–injected control Myd88fl/fl and Tie2-Cre;Myd88fl/fl
mice. All data represent mean 6 standard deviation
from 2 or 3 independent experiments. Two-tailed
Student t tests were used to assess statistical signifi-
cance (**P , .01, ***P , .001).
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for sensing LPS, translating this signal into G-CSF release, and
consequently initiating emergency granulopoiesis.
To assess expression of Tlr4 andMyd88 in ECs, we isolated CD452
Ter1192CD311ECs fromBM,heart, lung, liver, spleen, andkidneyand
compared these with pooled spleen classical and plasmacytoid dendritic
cells with deﬁned TLR expression patterns.42 No immunophenotypical
differences were observed between ECs from different organs with
respect to the endothelial markers VE-cadherin, CD105, CD34, and
Sca1 (data not shown). Myd88 and Tlr4 were abundantly expressed in
ECs at similar or higher levels compared with dendritic cells, ie, cell
populations known for their TLR expression proﬁle (Figure 3A-B).20
To analyze the functional relevance of Tlr4 and Myd88
expression in ECs, we injected mice with LPS or PBS (Figure 3C);
isolated ECs from BM, heart, lung, liver, spleen, and kidney; and
assessedG-csf transcripts byquantitative real-time PCR.Although in
the PBS-injected steady-state mice,G-csfwas only detectable at very
low levels, LPS injection resulted in a strong upregulation of G-csf
(up to several hundred-fold) in ECs from all organs analyzed
(Figure 3D). Interestingly,G-csf inductionwas relatively highest in
ECs from BM (ie, the primary site of hematopoiesis). However, it
needs to be emphasized that this does not necessarily imply that
absolute G-CSF amounts produced are also highest in this tissue.
Transcription and protein production do not always correlate, and
quantity of protein produced in a given organ will also depend on
frequency of producing cells at site.
To test whether there might be heterogeneity in the responsive-
ness toward LPS within different sections of the vasculature, we
analyzed the activation status of ECs upon systemic LPS stimulation
by measuring VCAM1 cell-surface expression.43 However, we did
not detect differences between ECs isolated from different tissues
and, importantly and in line with the observed nonresponsiveness,
VCAM1 upregulation on ECs was abrogated in Tie2-Cre;Myd88ﬂ/ﬂ
mice (Figure 3E and data not shown).
To conﬁrm that disruptedMYD88 signaling inTie2-Cre;Myd88ﬂ/ﬂ
mice does not affect G-CSF signal transduction and consequently
impairs emergency granulopoiesis, we injected Myd88ﬂ/ﬂ and Tie2-
Cre;Myd88ﬂ/ﬂ mice with recombinant human G-CSF (Figure 3F). In
accordance with our previously published data on G-CSF effects in
Tlr42/2mice,23 we observed that G-CSF alone without an additional
inﬂammatory stimulus is sufﬁcient to accurately mimic emergency
granulopoiesis (Figure 3G-I and data not shown).
Given the possibility of insufﬁcient tissue speciﬁcity ofCre-loxP
technology,we generatedTie2-Cre-loxP-GFP reportermice to study
the effectiveness and speciﬁcity of EC targeting. To this end, we iso-
lated nonhematopoietic cells from BM, heart, liver, kidney, spleen,
and lung and analyzed both GFP and expression of the EC marker
CD31 by FACS (Figure 4A-D). In accordance with previously
published reports,37 we found that the vast majority of ECs (approxi-
mately 90%)wereefﬁcaciously targeted inTie2-Cre-loxP-GFP reporter
mice. This pattern was robustly observed in all tissues analyzed, except
Figure 4. Endothelial cells are effectively targeted
in Tie2-Cre-loxP-GFP reporter mice and are the
main source of G-csf after in vivo LPS stimulation.
(A) Graphical scheme depicting experimental outline
to induce LPS-induced emergency granulopoiesis and
to assess G-csf expression in sorted CD452Ter1192
GFP1CD311 ECs and CD452Ter1192GFP1CD312 non-
ECs isolated from different organs of Tie2-Cre-loxP-GFP
reporter mice. (B) Representative FACS profile of GFP
and CD31 expression within nonhematopoietic cells
(CD452Ter1192) isolated from BM, heart, liver, kidney,
spleen, and lung of Tie2-Cre-loxP-GFP reporter mice.
(C) Percentages of CD311 (black bars) and CD312
(white bars) cells within the CD452Ter1192GFP1 cell
population in BM, heart, liver, kidney, spleen, and lung
of Tie2-Cre-loxP-GFP reporter mice. (D) Percentages
of CD311 (black bars) and CD312 (white bars) cells
within the CD452Ter1192GFP2 cell population in BM,
heart, liver, kidney, spleen, and lung of Tie2-Cre-loxP-
GFP reporter mice. (E) Comparative G-csf transcript
levels normalized to Actb in sorted CD452Ter1192
GFP1CD311 ECs (red bars) vs CD452Ter1192
GFP1CD312 non-ECs (white bars) isolated from
BM, heart, liver, kidney, spleen, and lung of LPS-
injected Tie2-Cre-loxP-GFP reporter mice. All data
represent mean 6 standard deviation from 2 indepen-
dent experiments (n5 5 mice). Two-tailed Student t tests
were used to assess statistical significance (*P , .05,
**P , .01, ***P , .001).
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for the lung, where we found a higher fraction of CD311 cells within
the CD452Ter1192GFP2 fraction (Figure 4B-D). Furthermore, we
observed that about 20% (with some variations between the different
tissues) of CD452Ter1192GFP1 cells in Tie2-Cre-loxP-GFP reporter
mice do not express the EC marker CD31 and thus, presumably, are
not ECs (Figure 4B-C).
To evaluate the role of these CD452Ter1192GFP1CD312 cells
for the initiation of emergency granulopoiesis, we injected Tie2-Cre-
loxP-GFP reportermicewithLPS, sorted theCD311ECandCD312
non-EC fractions of the CD452Ter1192GFP1 nonhematopoietic
compartment and comparedG-csf expression by quantitative reverse-
transcription PCR as a surrogatemarker for the ability of the respective
cell type to stimulate emergency granulopoiesis (Figure 4A). There
was no difference in steady-state G-csf expression between both
cell fractions (data not shown), whereas after LPS injection,G-csf
expression in CD452Ter1192GFP1CD311 ECs was always
Figure 5. Endothelial cell–intrinsic MYD88 signaling is required to stimulate accelerated neutrophil production, myeloid progenitor lineage skewing toward
granulocyte-macrophage progenitors (GMPs), and increased CFU-G activity in vivo. (A) Graphical scheme depicting experimental outline to induce LPS-induced
emergency granulopoiesis and to assess BrdU incorporation. (B) Representative FACS profile showing BrdU incorporation in in BM CD11b1Gr1high mature and BM
CD11b1Gr1low immature neutrophils in control Myd88fl/fl, and Tie2-Cre;Myd88fl/fl mice during steady-state and LPS-induced emergency granulopoiesis. (C) Frequencies of
BrdU1 BM CD11b1Gr1high mature and (D) BrdU1 BM CD11b1Gr1low immature neutrophils in PBS- or LPS-injected Myd88fl/fl and Tie2-Cre;Myd88fl/fl mice. (E)
Representative FACS profile showing myeloerythroid progenitors in control Myd88fl/fl, and Tie2-Cre;Myd88fl/fl mice during steady-state and LPS-induced emergency
granulopoiesis. (F) Frequencies of Lin2cKit1Sca12FcgR1CD341 GMPs in PBS- or LPS-injected Myd88fl/fl and Tie2-Cre;Myd88fl/fl mice. (G) Absolute CFU numbers
per 1 hind leg in control Myd88fl/fl and Tie2-Cre;Myd88fl/fl mice during steady-state and LPS-induced emergency granulopoiesis (CFU-G, CFU granulocyte; CFU-M, CFU
macrophage; CFU-GM, CFU granulocyte/macrophage; CFU-GEMM, CFU granulocyte/erythrocyte/macrophage/megakaryocyte; BFU-E, burst-forming unit erythrocyte). Black
squares, PBS-injected mice; red squares, LPS-injected mice. Data from 2 independent experiments are shown. Two-tailed Student t tests were used to assess statistical
significance (*P , .05, ***P , .001).
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signiﬁcantly higher (2- to 5-fold) than in the CD452Ter1192GFP1
CD312 non-EC fraction in all organs analyzed (Figure 4E). Thus,
given the 4-fold higher numbers of CD452Ter1192GFP1CD311
ECs vs CD452Ter1192GFP1CD312 non-ECs and the 2- to 5-fold
higher amount ofG-csf expression in CD452Ter1192GFP1CD311
ECs vs CD45-Ter1192GFP1CD312 non-ECs, we infer that most
(.95%) of G-CSF derived from ECs and, importantly, Tie2-Cre
mice, are a valid tool to assess ECs within the nonhematopoietic
compartment.
Collectively, ECs are equipped with the functional machinery
to detect LPS and are indeed the dominant G-CSF–producing cell pop-
ulation upon systemic LPS challenge, sufﬁcient to induce emergency
granulopoiesis.
EC-intrinsic MYD88 signaling is required to stimulate
accelerated neutrophil production, myeloid progenitor lineage
skewing toward granulocyte-macrophage progenitors, and
increased CFU-G activity in vivo
Next, we assessed neutrophil generation in the BM of Myd88ﬂ/ﬂ
and Tie2-Cre;Myd88ﬂ/ﬂ mice in the steady state and during LPS-
induced emergency granulopoiesis (Figure 5A). During 12 hours,
approximately 10% and 50% of BM CD11b1Gr1high mature and
BM CD11b1Gr1low immature neutrophils incorporated BrdU into
newly synthesized DNA in PBS-injected control and Tie2-Cre;
Myd88ﬂ/ﬂ mice, respectively (Figure 5B-D). After LPS injection,
there was a signiﬁcant increase in BrdU incorporation inMyd88ﬂ/ﬂ
mice in both BM CD11b1Gr1high mature and BM CD11b1Gr1low
immature neutrophils. However, this increase was absent in LPS-
injected Tie2-Cre;Myd88ﬂ/ﬂ mice (Figure 5B-D). These results
demonstrate that neutrophil turnover is signiﬁcantly accelerated
upon LPS stimulation, and that this response is dependent on EC-
intrinsic MYD88 signaling.
We also analyzed the myeloid progenitor compartment in
steady-state and LPS-injected Myd88ﬂ/ﬂ and Tie2-Cre;Myd88ﬂ/ﬂ
mice. In accordance with previously published results,44 we observed
an increase in the percentage of Lin2cKit1Sca12FcgR1CD341
granulocyte-macrophage progenitors (GMPs) upon LPS stimulation
in Myd88ﬂ/ﬂ mice. This response was absent in Tie2-Cre;Myd88ﬂ/ﬂ
mice (Figure 5E-F). These data demonstrate that LPS induces a
lineage bias at the HPC level in favor of enhanced granulopoiesis.
Finally, we determined the CFU activity in BM from steady-state
or LPS-injected Myd88ﬂ/ﬂ and Tie2-Cre;Myd88ﬂ/ﬂ mice. After LPS
injection, there was a signiﬁcant increase in the overall number of
CFUs in Myd88ﬂ/ﬂ mice. Notably, this increment was due to an
increase in CFU-granulocyte (CFU-G) with no changes in the
number of other CFU types. Importantly, this response was absent
in LPS-treated Tie2-Cre;Myd88ﬂ/ﬂ mice (Figure 5G).
Taken together, these data unambiguously demonstrate that,
besides its many known biological effects, including stimulation of
hematopoietic stem cell division45 and of neutrophil migration and
recruitment to inﬂamed tissues,14,15 LPS stimulates emergency
granulopoiesis via MYD88 signaling in ECs.
EC-intrinsic MYD88 signaling is required to efficiently stimulate
emergency granulopoiesis during systemic E coli infection
To evaluate whether MYD88 signaling in ECs is also important to
initiating emergency granulopoiesis in a far more complex setting
of infection with living bacteria, we performed experiments with
Figure 6. Endothelial cell–intrinsic MYD88 signaling
is required to efficiently stimulate emergency gran-
ulopoiesis during systemic E coli infection. (A)
Frequency and absolute number of PB CD11b1 cells,
(B) BM cellularity, (C) frequencies and absolute numbers
of BM CD11b1Gr1high mature and (D) BM CD11b1Gr1low
immature neutrophils, and (E) plasma G-CSF levels in
Myd88fl/fl mice and Tie2-Cre;Myd88fl/fl mice in steady-state
(black squares) and after infection with 4.5 3 108 E coli
CFU (red squares) given IP. Data from 2 independent
experiments are shown. rel., relative; abs., absolute.
Two-tailed Student t test was used to assess statis-
tical significance (**P , .001, ***P , .001).
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E coli. First, we titrated the E coli dose necessary to elicit a similar
quantitative response in WT mice as observed with the LPS dose
used in prior experiments. We determined this dose to be 4.53 108
E coli CFU given IP per WT mouse (supplemental Figure 3A-E).
In parallel, we also infectedMyd882/2 mice. Although these mice
showed some response to E coli, the responses were severely and
highly signiﬁcantly reduced compared with WT mice for the entire
previously assessed readouts characteristic for emergency granulo-
poiesis (supplemental Figure 3A-E). Importantly, the minor MYD88-
independent responses upon E coli infection are also independent of
G-CSF because there was no signiﬁcant rise in plasma G-CSF
levels in Myd882/2 mice (supplemental Figure 3E).
Next, we infected control Myd88ﬂ/ﬂ and Tie2-Cre;Myd88ﬂ/ﬂ mice
with E coli (4.53 108 CFU per mouse). We observed the same pattern,
withMyd88ﬂ/ﬂmice showing the same response as WTmice, and Tie2-
Cre;Myd88ﬂ/ﬂmice showingaminor, in comparisonwithMyd88ﬂ/ﬂmice
signiﬁcantly reduced response. This indicates that EC-intrinsicMYD88
signaling is required to induce full-blown emergency granulopoiesis
also upon live E coli infection (Figure 6A-E). The minor response
observed in Tie2-Cre;Myd88ﬂ/ﬂmice in an infection with live bacteria
might not be surprising because in this far more complex situation,
in contrast to exclusive LPS-mediated stimulation, other pattern-
recognition receptor agonists and additional tissue damage also might
activate alternative, independent signaling pathways. Notably,
however, plasma G-CSF levels did not rise above steady-state
levels in Tie2-Cre;Myd88ﬂ/ﬂ mice, revealing ECs to be major
sources of G-CSF also during infection with E coli (Figure 6E).
To test whether TLR adaptor TRIF might partially compensate
for the severely diminished E coli–induced emergency granulopoi-
esis inMyd882/2 and Tie2-Cre;Myd88ﬂ/ﬂmice, and to determine the
relative contribution of each pathway to it, we infectedWT, Tlr42/2,
Myd882/2, and Trif2/2 mice with 4.5 3 108 E coli CFU IP. We
observed that both Tlr42/2 and Myd882/2 mice show an equally
reduced ability to launch emergency granulopoiesis compared
with WT mice. By stark contrast, Trif2/2 mice responded to E coli
(supplemental Figure 4) with emergency granulopoiesis, as did
WTmice. These data demonstrate that TRIF is dispensable for the
initiation of emergency granulopoiesis.
In summary, our ﬁndings demonstrate that abrogated
MYD88 signaling in ECs leads to severely defective emergency
granulopoiesis upon E coli infection.
Discussion
We addressed here the fundamental question of which cell types act
as primary sensors of bacterial dissemination during severe infection
and consequently induce the switch from steady-state to demand-
adapted emergency granulopoiesis.
Twogeneralmodels have beenproposed for howpathogen sensing
and translation into emergency granulopoiesis may be achieved.7,8
According to the concept of indirect hematopoietic activation, tissue-
resident macrophages might serve in this critical function46,47
because they indeed express pattern-recognition receptors, and, after
respective stimulation, produce granulopoietic growth factors.48-51
But data from stringent in vivo experimentation supporting this
model are lacking. Alternatively, several recent studies suggested
a model of direct hematopoietic activation based on the observation
that mouse and human HSPCs express TLRs and that TLR agonist
stimulation leads to enhanced myelopoieisis.16-19,21 However, these
studies used either in vitro16 or very speciﬁc in vivo experiments such
as adoptive HSPC transfer under the renal capsule,18 direct injection
of HSPCs into Staphylococcus aureus–infected wounds,21 or pre-
treatment with chemotherapeutic agents and ionizing radiation22
to convey their respective proposed model. By contrast, we have
demonstrated that pathogen sensing by both immature HSPCs and
mature hematopoietic cells, including macrophages, is dispensable
for the acute process of emergency granulopoiesis in 3 independent
and complementary experimental approaches. First, in both hema-
topoietic Tlr42/2 chimeric mice23 and hematopoietic Myd882/2
chimeric mice, emergency granulopoiesis is indistinguishable from
that in WT mice. Of note, we and others could show that BM
chimeric mice are an appropriate tool to broadly dissect biological
effects contributed by either hematopoietic or nonhematopoietic
tissues by conﬁrming that tissue-resident macrophages, although they
are able to locally self-renew in the steady state,52 are replenished by
donor-derived cells after lethal irradiation.23,52 Second, liposomal
clodronate–mediated macrophage-depleted WT mice launch
undiminished emergency granulopoiesis upon LPS stimulation.23
Third, as shown here, mice with aMyd88-deﬁciency in the myeloid
compartment, most importantly macrophages (LysM-Cre;Myd88ﬂ/ﬂ
mice), respond normally toward LPS with emergency granulopoiesis.
To determine the identity of the nonhematopoietic cell types re-
quired for the initiation of emergency granulopoiesis, we undertook
an extensive genetic targeting approach using Cre recombinase–
mediated tissue-speciﬁcMyd88 ablation. Speciﬁcally,we targeted the
nonhematopoietic BM microenvironment (Nestin1mesenchymal stem
cells andperivascular stromal cells) usingNes-Cre36-38 andPdgfrb-Cre39
Figure 7. Model for pathogen sensing and subsequent translation into emergency
granulopoiesis. (1) Gram-negative bacteria and/or their structural components that
have gained access to the systemic circulation are recognized by TLR4-expressing
endothelial cells (2), thereby indicating an emergency state. Upon TLR4/MYD88 signaling
in endothelial cells, G-CSF is released in large quantities (3). In the bone marrow,
endothelial cell–derived G-CSF acts on myeloid precursors expressing the G-CSF
receptor resulting in enhanced generation, accelerated turnover, and increased neutrophil
release from the bone marrow to the systemic circulation (4). These neutrophils are
recruited to the site of infection (5) where they participate in clearing the pathogen (6).
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mice.These cells have been shown to be part of the hematopoiesis-
supporting BM microenvironment.53 Vascular cells (ECs and
pericytes) were targeted using Tie2-Cre37,38,40,54 and Pdgfrb-Cre39
mice, respectively. In addition, we used Alb-Cre41 mice to target
hepatocytes as a candidate prototypic parenchymal cell type. Our
data revealed that ECs express high amounts of Tlr4 andMyd88 and
respond to systemic LPS stimulation or E coli infection with massive
upregulation of the primary granulopoiesis-supporting growth factor
G-CSF. Most importantly, mice with a Myd88 deﬁciency in ECs
do not respond with emergency granulopoiesis upon systemic LPS
stimulation and have a severely defective response toward E coli
infection. The E coli–drivenMYD88- and G-CSF–independent minor
responses in Myd882/2 and Tie2-Cre;Myd88ﬂ/ﬂ mice are likely
triggered by activation of alternative, redundant pathways that evolved
to secure this critical response. Of interest, a recent study showed that
granulopoiesis after antibody-mediated neutrophil removal depends
on TLR4/TRIF signaling.55 We therefore studied whether a similar
feedback regulatory mechanism via TLR4/TRIF might account for
the residual emergency granulopoiesis observed in E coli–infected
Myd882/2 andTie2-Cre;Myd88ﬂ/ﬂmice.However, we observed that
TLR4 signal transduction via TRIF is dispensable for the induction
of E coli–driven emergency granulopoiesis as Trif2/2 mice show
a response that is indistinguishable from those in WT mice.
Because congenital33 or iatrogenic32 forms of neutropenia are
associated with a high incidence of lethal infectious complications, it
seems very likely that the ability to induce emergency granulopoiesis
per se has a live-saving role in massive infection. However, direct
experimental evidence for this notion is lacking and future studies
will need to dissect emergency granulopoiesis from neutrophil
recruitment to inﬂamed tissues and neutrophil effector functions,
which together ensure host survival during bacterial infection.
Given the general caveat of lack of absolute tissue speciﬁcity in
theCre-loxP system, we have analyzed Tie2-Cre-loxP-GFP reporter
mice. In accordance with the literature,37,38,40,54 Tie2-Cre mice are
an excellent tool to genetically manipulate ECs, but, of note, there is
also a small fraction of other (ie, non-EC and nonhematopoietic) cells
targeted in Tie2-Cre mice. However, we have addressed this issue
experimentally by analyzing the G-CSF response in non-ECs in
these mice and could exclude a relevant contribution of these
nonhematopoietic, non-EC cell populations to the overall emer-
gency granulopoiesis response.
Interestingly, the versatile and critical function of endothelium is
an emerging aspect in hematopoiesis research. It has recently been
demonstrated that ECs are an important constituent of the BM
microenvironment. Using a similar genetic tissue-speciﬁc deletion
approach, ECs were shown to be major sources of stem cell factor37
and CXCL12,38,54 2 molecules that are involved in HSPC main-
tenance and their BM retention, respectively. Our results now show
that ECs are not only critical for the regulation of steady-state
hematopoietic maintenance but are also essential for demand-
adapted hematopoiesis in response to the paradigmatic gram-negative
bacteria–derived compound LPS and the clinically relevant pathogen
E coli. In conjunction with previously published data on the
importance of TLR signaling in ECs for neutrophil recruitment to
inﬂamed tissues,14,15 our ﬁndings reveal a sophisticated degree of
functional interplay between the vascular, the hematopoietic, and the
immune systems, which have a common developmental root and
might thus be understood as 1 functional organ.56,57 Of note, our
ﬁndings also conﬁrm and extend prior landmark observations on
the importance of nonhematopoietic cell-derived hematopoietic
growth factors.58,59 Although these seminal studies established
a role for nonhematopoietic cells as a major source of hematopoietic
growth factors, they, because of technical limitations at that time,
were unable to identify the precise identity of this cell type that we
now show to be ECs.
ECs are ideally positioned to mark the threshold of local vs
systemic infection, and using ECs as safeguards seems a very
plausible, danger-adapted defense strategy established in evolution.
In summary, based on the data presented here, we propose a model
(Figure 7) in which ECs are critical for pathogen sensing and
subsequent induction of emergency granulopoiesis.
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Discussion & Outlook 
It is well-established that the BM microenvironment plays an essential role in regulating the various 
aspects of steady-state hematopoiesis [60, 61, 64, 72-78, 80, 87-90]. Moreover, accumulating 
evidence suggests that non-hematopoietic BM cells also contribute to the hematopoietic system’s 
adaptation to stress-induced also termed ‘emergency hematopoiesis’ [46, 56]. Therefore, we here 
addressed the question which regulatory signals are provided by non-hematopoietic cells of the 
BM microenvironment to govern the switch from steady-state to inflammation- and infection-driven 
hematopoiesis and to sustain the latter during an ongoing inflammatory process. To this end, we 
planned to mimic severe systemic bacterial or viral infection by applying LPS or poly(I:C), 
respectively, followed by flow-cytometrically sorting different non-hematopoietic BM cell types for 
subsequent RNA extraction and expression analysis. 
As non-hematopoietic cell types in the BM comprise only around 0.1-0.8% of total cells, we 
undertook an extensive effort to establish and optimize a protocol for the prospective isolation of 
non-hematopoietic BM cell types. Using cell surface markers CD45 and Ter119 to exclude 
hematopoietic cells in combination with Sca-1, CD31, CD105 and CD140b, several non-
hematopoietic BM cell types could be flow-cytometrically defined and robustly isolated from mouse 
BM: sinusoidal endothelial cells (SECs, CD45-Ter119-CD31+CD105hiSca-1int), arteriolar endothelial 
cells (AECs, CD45-Ter119-CD31+CD105intSca-1hi), mesenchymal stromal cells (MSCs, CD45-
Ter119-CD31-Sca1+CD140b+), and CXCL12-abundant reticular cells (CAR cells, CD45-Ter119-
CD31-Sca1-CD140b+). As a pilot study, we conducted a first RNA sequencing run on one replicate 
of PBS, LPS and poly(I:C) treated mice with the intention to perform quality control analyses. We 
analyzed the expression levels of cell surface markers CD45, Sca1, CD105 and CD140b used for 
the prospective isolation of the different non-hematopoietic BM cell types. All analyzed genes 
showed the expected distribution among cell population, except for CD45 which was elevated in 
the quintuple-negative cell population suggesting that this population contains to some extent also 
hematopoietic cells. In addition, we also examined the expression levels of different housekeeping 
genes among all cell types in all conditions and could see that they are evenly expressed. We then 
also analyzed the expression of Kitl and Cxcl12 demonstrating that expression of these genes is 
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largely restricted to ECs and CARs thereby confirmig previously published data [64, 71-73]. 
Principal component analysis indicated that samples of the same cell types of different conditions 
clustered tightly with the exception of AECs and SECs. This might be due to a not restrictive 
enough gating strategy during sorting. Alternatively, Sca-1 – a known Interferon-inducible gene – 
becomes up-regulated after LPS and poly(I:C) treatment and consequently SECs exhibit higher 
Sca-1 expression during inflammatory conditions as opposed to steady-state and become less well 
separable from AECs. Thus, a more restrictive gating will be applied for future experiments.  
In summary, we were able to establish a sorting strategy for different non-hematopoietic 
BM cell populations from different conditions with subsequent RNA extraction and RNA 
sequencing gave us promising results in quality and quantity controls. With the confidence that our 
newly established protocol fulfils the expectations of providing enough RNA with a good quality, we 
are planning to sort AECs, SECs, MSCs, CARs and Unkn from LPS and poly(I:C) treated adult WT 
mice and from young and aged animals. Subsequently, all samples will be sequenced and the data 
will be analyzed of differential gene expressions of young, old and inflammation-induced mice. 
These future experiments hold the promise to be informative on the similarities and distinctions 
between non-hematopoietic BM stromal cell subpopulations in their hematopoiesis-supporting 
capacity during ageing and inflammation. 
 
Having established the prospective isolation method for non-hematopoietic BM stromal cell 
subsets, we chose to analyze gene expression changes of twelve candidate hematopoietic growth 
factors and inflammatory cytokines with well known functions in steady-state and inflmmation-
induced hematopoiesis. Kitl, FLT3L, TPO, GM-CSF and G-CSF are important factors in the 
regulation of HSCs and HSPCs. The continuous expression of Kitl is required for the maintenance 
of normal hematopoiesis which is achieved by binding to its receptor cKIT which is expressed on 
all HSPCs [142]. FLT3L is a growth factor for HSPCs and induces HSPC mobilization and is 
important in dendritic cell (DC) homeostasis [143, 144]. TPO is involved in HSC maintenance 
during steady-state and supports HSC expansion after transplantation [145, 146]. G-CSF and GM-
CSF initiate proliferation and differentiation of HSPCs into mature granulocytes and monocytes. G-
CSF is also used in clinics to mobilize HSCs into PB [147] and is highly upregulated during 
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bacterial infection to induce emergency granulopoiesis [56]. The other analyzed cytokines were 
known to have a functional role during infection. INFα and INFβ are type I interferons and are 
essential in the anti-viral response [148]. They are secreted by infected cells and induce an anti-
viral state in neighboring cells to limit the spread of the virus. In addition they help to balance the 
innate immune reaction and activate the adaptive immune system by promoting the development 
of antigen-specific T and B cells [148]. TNFα is involved in pro-inflammatory responses to systemic 
inflammation and is one of the cytokines that make up the acute phase reaction [101]. TNFα is not 
only involved in inflammation but also in processes like cellular communication, cell differentiation 
and cell death [149]. In addition, also different interleukins were analyzed, i.e. IL-1α, IL-1β, IL-3 
and IL-6. IL-1 and IL-6 are like TNFα involved in the acute phase response and are pro-
inflammatory signals [101]. IL-6 can also act as anti-inflammatory cytokine depending on the 
context and has many more described functions like maturation of B cells into antibody-secreting 
plasma cells [102, 103] and T cell expansion and activation [104-106, 150]. IL-6 was also shown to 
be important in the immune response against viral or bacterial infections and survial and self-
renewal of HSPCs [111, 112]. The two subtypes of IL-1 are distinctly regulated but show similar 
biological activities like T cell differentiation [151]. IL-3 has similar functions on hematopoiesis like 
GM-CSF and therefore is acting on progenitor cells to regulate the development into multiple 
lineages and hence also supports growth and differentiation of T cells as immune response [152, 
153]. Although function and expression of these twelve cytokines have been studied extensively, 
little is known about their primary cellular source during inflammatory conditions. Our RT-qPCR-
based expression analysis could confirm some previously published results. For example, Kitl was 
found to be expressed mainly by ECs and CARs in steady-state [73]. Furthermore, Csf3 was highly 
upregulated in AECs after LPS treatment [56]. Remarkably, we did not observe relevant 
upregulation of Il1β, TNFα or Infβ in any of the non-hematopoietic BM stromal cells after LPS or 
poly(I:C) treatment although these are all target genes of the NFkB pathway [154, 155]. NFkB can 
be activated by many different bacteria and viruses and hence regulates the expression of 
inflammatory cytokines [155, 156]. However, the activation of these target genes of the NFkB 
pathway has mainly been studied in cells of the immune system but not in non-hematopoietic BM 
cells possibly explaining this observation.  
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The most prominent result from our initial gene expression analysis in non-hematopoietic 
BM stromal cells  was the high upregulation of Il6 specifically in CAR cells after LPS treatment but 
not poly(I:C) treatment. As IL-6 is a pleiotropic cytokine with many described functions, we 
focussed our efforts on IL-6 and set out to unravel its regulatory role on the hematopoietic system 
during gram-negative bacterial infection, mimicked by LPS administration.  
 
To determine whether CAR cells are a relevant source of IL-6 we first examined Il6 transcription in 
major solid organs and total bone upon LPS treatment. Surprisingly, we observed that Il6 was 
significantly highest up-regulated in total bone as compared to the other organs. We then also 
analyzed IL-6 protein levels in plasma and BM lysates of reciprocal Il6-/- BM chimeras where Il6 
expression is restricted either to hematopoetic (WT à Il6-/-) or non-hematopoietic cells (Il6-/- à 
WT). We could observe highly elevated IL-6 protein levels in plasma and BM upon LPS treatment 
only if non-hematopoietic cells were Il6-competent indicating that a non-hematopoietic BM cell type 
is the major source of IL-6. To further investigate whether this cell type might be indeed CAR cells 
as suggested by our gene expression analysis from prospectively isolalated non-hematpoietic BM 
stromal cells, we bred Lepr-cre mice, which relative specifically target CAR cells [73, 77], with Il6fl/fl 
mice to generate animals deficient in IL-6 production in CAR cells. The IL-6 protein levels in this 
Lepr-Cre;Il6fl/fl mice were completely abrogated after LPS treatment compared to control mice 
revealing that CAR cells are indeed the major source of IL-6. 
 
If we followed IL-6 protein levels during chronic-repetitive LPS administration over a period of 3 
weeks, we were able to detect increased IL-6 levels, however, to a lower extent than after the first 
injection. A possible explanation could be a mechanism called endotoxin tolerance (ET), which can 
occur during chronic bacterial infection. ET is a protective mechanism to prevent excessive 
inflammation that could lead to a septic shock and has mostly been studied in phagocytic immune 
cells. Monocytes and macrophages enter an unresponsive state after repeated exposure to 
endotoxins (e.g. LPS) and hence show an inability to respond to further LPS challenges [140, 141]. 
Many inflammatory cytokines like TNFα, IL-6, IL-12, IL-1β, CCL3, CCL4 and CXCL10 are 
downregulated after recurring exposure to LPS [141, 157]. Also other myeloid cells like DCs and 
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neutrophils have been shown to undergo ET and these cells also downregulate inflammatory 
cytokines such as TNFα, IL-6 and IL-12. However, whether ET also occurs in CAR cells after 
repetitive LPS treatment remains to be clarified. Importantly, despite the observed decline in the 
magnitude of IL-6 protein levels, these remain significantly elevated in LPS-treated mice compared 
to control animals and thus, will likely be biologically active. 
 
Having confirmed that CAR cells are the major producer of IL-6 after LPS stimulation, we wanted 
to study the functional relevance of IL-6 during emergency hematopoiesis. Hence, we used a well-
established model of emergency granulopoiesis. WT and Il6 -/- mice were injected twice with LPS 
in a 48 hour interval and analyzed 24 hours after the last injection. We assessed relative and 
absolute changes in HSPC and myeloid cell numbers between LPS treated WT and Il6-/- mice, but 
no differences were detected demonstrating that IL-6 is dispensable for emergency granulopoiesis 
at least during short-term LPS-induced inflammation.  
These results prompted us to investigate whether IL-6 would only become relevant for emergency 
hematopoiesis during chronic-repetitive LPS-induced inflammation. Therefore, we injected WT and 
Il6-/- mice 9 times over a period of 3 weeks and analyzed HSPC and myeloid cell numbers 24 
hours after the last injection. We could observe that LPS-treated Il6-/- mice had a significantly 
attenuated increase in their absolute cell numbers of HSCs and HPCs. Moreover, GMPs and more 
mature myeloid cells even decreased in absolute numbers following chronic-repetitive LPS 
stimulation. Therefore, mice deficient in IL-6 fail to sustain an adequatetely quantitative emergency 
hematopoietic response during chronic inflammation-driven hematopiesis. In order to investigate 
whether the lack of CAR cell-produced IL-6 is responsible for the failure in generating adequate 
amounts of HSPCs and mature myeloid cells during chronic-repetitive LPS-induced inflammation, 
we repeated the long-term LPS injections with Lepr-Cre;Il6fl/fl mice and their respective controls. 
We could observe the exact same failure of maintaining a hematopoietic response upon chronic-
repetitive LPS stimulation. Importantly, to not only quantitatively assess numbers of 
immunophenotypically-defined HSPC and myeloid cells populations but also functionally test the 
role of IL-6 in HSPC biology during chronic inflammation, we performed CFU assays to test HSPC 
functionaltiy in vitro. To this end, we subjected total BM of Il6-/- and Lepr-Cre;Il6fl/fl mice upon 
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chronic-repetitve LPS-treatment and their respective controls to fully cytokine-supplemented CFU 
assays. As expected, we could observe a significant increase in total CFUs in LPS-treated control 
animals compared to PBS treated mice mainly due to a high increase of CFU-Gs. Not only was 
there no such increase detectable in LPS-treated Il6 -/- mice or Lepr-Cre;Il6fl/fl mice compared to 
PBS treated animals but there was even a decrease in CFU activity. Collectively, these data 
clearly demonstrate that CAR cell-produced IL-6 is required for emergency hematopoiesis and 
sustained hematopoietic output from HSPCs during chronic-repetitive inflammation.  
 
IL-6 is known to promote hematopoiesis [112] but detailed insights into its mode of action are 
lacking. Using novel technologies, two recent papers have expanded our knowledge of the role of 
IL-6 during inflammation-induced emergency hematopoiesis [39, 57]. Zhao et al. investigated the 
response of single HSPCs toward TLR agonists in vitro using a proteomic approach. HSPCs were 
shown to respond to TLR agonist treatment with the secretion of a variety of inflammatory 
cytokines. Rigorous functional validation of this interesting finding was hampered by the 
unavailability of clean experimental methods to specifically and most importantly, exclusively 
ablate Il6 from only HSPCs but leaving differentiated myeloid progeny unaffected. The authors 
therefore had to circumvent this problem by using very specific experimental conditions consisting 
of transplanting BM from WT or Il6-/- donor mice into severely leukopenic hosts devoid of 
endogenous HSPCs followed by LPS stimulation. Under these experimental conditions, 
transplanted donor WT HSPCs were more efficient to generate myeloid offspring as compared to 
HSPCs from Il6-/- donor mice. By contrast, our findings unequivocally demonstrated that CAR cells 
are the major source of IL-6 upon LPS stimulation. These contradictory findings are most likely due 
to the different experimental approaches used. The findings by Zhao et al. suggest that HSPC-
derived IL-6 may play a role in compensating for growth factor deficiencies resulting from a 
transiently dysfunctional BM microenvironment following recovery from myeloablative 
hematopoietic stem cell transplantation. Notably, our findings, however, studying naturally-
occurring chronic infection / inflammation clearly reveal that IL-6 levels following chronic-repetitive 
LPS stimulation primarily depend on non-hematopoietic CAR cells.  
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Moreover, another recently published study described that IFN released from cytotoxic T 
cells during viral infection acts on BM MSCs leading to secretion of IL-6 which, in turn, promotes 
monopoiesis. It needs to be noted that MSCs and CAR cells are distinct cell populations and 
different types of inflammation (viral vs. bacterial) were used in the study by Schuerch et al. and 
ours. Nevertheless, in order to test whether T cells might be involved in IL-6 release from CAR 
cells following LPS stimulation we injected WT and Rag1-/- mice, which lack B and T cells due to a 
defect in immunoglobulin and TCR rearrangement, with LPS and PBS as control and measured 
systemic and local BM IL-6 levels. We still observed indistiguishable levels of IL-6 in LPS treated 
Rag1-/- mice compared to LPS treated WT animals clearly demonstrating that T cells are 
dispensable for IL-6 secretion from CAR cells upon LPS-induced inflammation. 
 Having shown that IL-6 plays a critical role in sustaining hematopoiesis following chronic-
repetitive LPS-induced inflammation, we set out to determine whether IL-6 acts directly or indirectly 
onto HSPCs to stimulate enhanced proliferation and differentiation. Although we cannot definitively 
prove direct IL-6 action on HSPCs, two lines of evidence suggest that this may indeed be the case. 
First, we found detectable expression of both CD126 (i.e. IL-6Rα) representing the ligand-binding 
subunit of the IL-6R as well as CD130 (i.e. gp130) representing the signal-transducing subunit on 
HSPCs by FACS. Second, c-Kit-enriched BM cells from WT mice subjected to CFU assays and 
grown in presence of IL-6 generated more myeloid colonies than control cells cultured in the 
absence of IL-6.  
 
Finally, we investigated whether LPS binds directly to CAR cells to activate IL-6 production and 
secretion or whether LPS sensing occurs in a different cell population which, in turn, stimulates IL-
6 release from CAR cells indirectly. Therefore, we assessed Toll-like receptor expression in CAR 
cells by RT-qPCR and found Tlr4, the cognate receptor for LPS, to be highly expressed on CAR 
cells demonstrating that CAR cells are in principle able to directly sense LPS and respond with an 
increased IL-6 secretion. In addition, we also measured IL-6 protein levels after LPS treatment in 
reciprocal Tlr4-/- BM chimeras in which Tlr4 expression is restricted to either hematopoetic (WT à 
Tlr4-/-) or non-hematopoietic(Tlr4-/-  à WT) cell types. After a single LPS injection, whereas local 
BM IL-6 levels depended on both TLR4 on hematopoietic as well as non-hematopoietic cell types, 
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systemic IL-6 levels fully depended on TLR4 on non-hematopoietic cells. By contrast, following 
chronic-repetitive LPS stimulation over 3 weeks systemic and local BM IL-6 levels were completely 
depended on TLR4-expressing non-hematopoietic cells. Although multiple non-hematopoietic cell 
types express TLRs [55] and no currently available experimental model system allows specific 
deletion of Tlr4 in CAR cells our above-described data suggest that CAR cells indeed integrate 
LPS sensing and IL-6 production within one cell type.  
 
In summary, we could demonstrate using different mouse models that CAR cells are the major 
producer of IL-6 during LPS stimulation and that IL-6 is necessary to sustain emergency 
hematopoiesis during chronic repetitive LPS stimulaiton. Importantly, our findings further 
emphasize that the BM microenvironment not only plays a critical regulatory role in steady-state 
but also during infection- and inflammation-driven hematopoiesis. A better understanding of the 
mechanisms operating during the hematopoietic system’s adaptation to infection and inflammation 
may hold the promise to devise new therapeutic interventions to treat infectious and inflammatory 
diseases. 
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Conclusions 
1. BM CAR cells are the primary source of systemic and local BM IL-6 levels after LPS 
stimulation. 
2. IL-6 is dispensable for emergency hematopoiesis during short-term LPS administration. 
3. IL-6 is required for an adequately quantitative increase in numbers of immunophenotypically-
defined HSPCs and differentiated myeloid cells during chronic-repetitive LPS-induced 
inflammation. 
4. IL-6 is essential to increase functional CFU activity during chronic-repetitive LPS-induced 
inflammation  
5. HSPCs express the IL-6 receptor α and β subunits and have therefore the ability to respond to 
IL-6 via cis- or trans-signaling.  
6. BM CAR cells express multiple Toll-like receptor genes including Tlr4, which renders them 
capable of direct LPS sensing. 
7. Systemic plasma and local IL-6 levels depend on Tlr4-expressing, non-hematopoietic cells.  
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Material and Methods 
Mice 
In this study C57BL/6J (Janvier) mice were used. All animals were maintained at the University 
Hospital Zurich animal facility and treated in accordance with guidelines of the Swiss Federal 
Veterinary Office. Experiments and procedures were approved by the Veterinäramt des Kantons 
Zurich, Switzerland. 
 
LPS and pIC injections  
Mice received 2 intraperitoneal injections of 35 µg ultrapure LPS from E. coli 0111: B4 (InvivoGen) 
or 100 ug poly (I:C) (InvivoGen) 48 hours apart and non-hematopoietic BM cell populations were 
prospectively isolated 4 hours after the last injection.  
 
Processing of bones 
Femurs, tibias and hip bones were removed, BM was flushed and cells were resuspended with 
digestion medium (DMEM/10% FCS/10mM HEPES/0.4% collagenase II (Worthington)/0.02% 
DNase I (Worthington)). Bones were cut into small pieces and combined with flushed BM in a total 
of 5 ml digestion medium. Bones and BM were incubated for 45 min at 37°C on a shaker and 
afterwards the cell suspension was filtered through a 70um cell strainer. LS MACS columns 
(Miltenyi Biotec) were then used to enrich the cell suspension for CD45-Ter119- cells following the 
supplier’s protocols. 
 
Flow cytometry 
The following antibodies (all from eBiosciences, unless otherwice stated) were used to assess and 
sort different non-hematopoietic BM stromal cell types: anti-Sca1 (D7, Biolegend), anti-Ter119 
(TER-119, Biolegend), anti-CD45 (30-F11, Biolegend), anti-CD31 (390), anti-CD105 (MJ7/18), and 
anti-CD140b (APB5). 
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RNA extraction 
AEC, SEC, MSC, CAR  and Unkn cell populations were sorted directly into RLT Lysis Buffer 
provided by Qiagen (RNeasy Micro Plus Kit). RNA was extracted following the supplier’s protocols. 
RNA quantities and qualities were measured using the 2200 TapeStation (Agilent Technologies).  
 
Sample preparation and Microarray analysis 
The WT-Ovation One-Direct System (Nugen) and Encore Biotin Module (Nugen) were used for the 
synthesis of cDNA and its fragmentation following the supplier’s protocol. The microarray analysis 
was performed on a Affymetrix Mouse Gene 2.0 ST Array chip containing 35'240 gene probes. 
 
RNA Seq library preparation and Sequencing 
600 pg of input total RNA were used for cDNA synthesis and the library preparation with the 
Clonetech SMRTer Stranded total RNA-Seq Kit for Pico Input Mammalian Total RNA. The library 
was sequenced using the Illumina HiSeq4000 instrument. 
 
Additional Material and Methods used for the Research article are listed in the section “Research 
article”. 
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